<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.0.8 on 13-Nov-2013 [10:33:58] {AM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:bcli="http://www.brainstorm-cell.com/20130930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="bcli-20130930.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2007To12_31_2007">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>

      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2008To12_31_2008">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>

      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2009To12_31_2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>

      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To01_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2010To02_28_2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>

      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2011To02_28_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>

      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2001To03_31_2002">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2001-04-01</xbrli:startDate>

      <xbrli:endDate>2002-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2002To03_31_2003">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2002-04-01</xbrli:startDate>

      <xbrli:endDate>2003-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2003To03_31_2004">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2003-04-01</xbrli:startDate>

      <xbrli:endDate>2004-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2004To03_31_2005">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-04-01</xbrli:startDate>

      <xbrli:endDate>2005-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2005To03_31_2006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-04-01</xbrli:startDate>

      <xbrli:endDate>2006-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2006To12_31_2006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-04-01</xbrli:startDate>

      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_21_2004">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2004-05-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To07_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To09_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2013To08_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>

      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To03_31_2001">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2001-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To09_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_12_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-11-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2009To12_24_2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-12-01</xbrli:startDate>

      <xbrli:endDate>2009-12-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2009">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_22_2000">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2000-09-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2001">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2001-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2002">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2002-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2003">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2003-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2004">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2004-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2005">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2005-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2007">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2008">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn09_22_2000_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2000-09-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_22_2000_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2000-09-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_22_2000_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2000-09-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_22_2000_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2000-09-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2001-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To03_31_2001_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2001-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To03_31_2001_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2001-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To03_31_2001_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2001-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2001-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2001_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2001-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2001_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2001-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2001_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2001-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2001To03_31_2002_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2001-04-01</xbrli:startDate>

      <xbrli:endDate>2002-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2001To03_31_2002_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2001-04-01</xbrli:startDate>

      <xbrli:endDate>2002-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2001To03_31_2002_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2001-04-01</xbrli:startDate>

      <xbrli:endDate>2002-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2001To03_31_2002_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2001-04-01</xbrli:startDate>

      <xbrli:endDate>2002-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2002_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2002-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2002_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2002-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2002_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2002-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2002_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2002-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2002To03_31_2003_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2002-04-01</xbrli:startDate>

      <xbrli:endDate>2003-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2002To03_31_2003_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2002-04-01</xbrli:startDate>

      <xbrli:endDate>2003-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2002To03_31_2003_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2002-04-01</xbrli:startDate>

      <xbrli:endDate>2003-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2002To03_31_2003_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2002-04-01</xbrli:startDate>

      <xbrli:endDate>2003-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2003_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2003-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2003_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2003-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2003_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2003-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2003_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2003-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2003-04-01</xbrli:startDate>

      <xbrli:endDate>2004-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2003To03_31_2004_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2003-04-01</xbrli:startDate>

      <xbrli:endDate>2004-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2003To03_31_2004_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2003-04-01</xbrli:startDate>

      <xbrli:endDate>2004-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2003To03_31_2004_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2003-04-01</xbrli:startDate>

      <xbrli:endDate>2004-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2004-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2004_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2004-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2004_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2004-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2004_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2004-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_21_2004_PurchaseAgreementMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcli:PurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2004-05-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_24_2009_InitialResearchPeriodMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bcli:InitialResearchPeriodMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-12-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_24_2009_ExtendedResearchPeriodMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bcli:ExtendedResearchPeriodMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-12-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2004To12_31_2004_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:EldadMelamedAndDanielOffenConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-01-01</xbrli:startDate>

      <xbrli:endDate>2004-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_ProfDanielOffenConsultantMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ProfDanielOffenConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2010_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:EldadMelamedAndDanielOffenConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:EldadMelamedAndDanielOffenConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_ProfDanielOffenConsultantMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ProfDanielOffenConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_ProfDanielOffenConsultantMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ProfDanielOffenConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_ConsultantsMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_ConsultantsMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ConsultantsMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateNovDec2004Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateNovDec2004Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFebDec2005Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFebDec2005Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFebDec2006Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFebDec2006Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateMar2007Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateMar2007Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApr2008Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApr2008Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateAprOct2009Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateAprOct2009Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2004To12_31_2004_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-01-01</xbrli:startDate>

      <xbrli:endDate>2004-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2005To02_28_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-02-01</xbrli:startDate>

      <xbrli:endDate>2005-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2005To12_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-01-01</xbrli:startDate>

      <xbrli:endDate>2005-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2005To08_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-08-01</xbrli:startDate>

      <xbrli:endDate>2005-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2005To09_30_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-09-01</xbrli:startDate>

      <xbrli:endDate>2005-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2005To12_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-12-01</xbrli:startDate>

      <xbrli:endDate>2005-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="invest:InvestmentAxis">bcli:InvestmentAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="invest:InvestmentAxis">bcli:InvestmentAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-07-01</xbrli:startDate>

      <xbrli:endDate>2007-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="invest:InvestmentAxis">bcli:InvestmentAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bcli:WarrantIssuedOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-07-01</xbrli:startDate>

      <xbrli:endDate>2007-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedTwoMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="invest:InvestmentAxis">bcli:InvestmentAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bcli:WarrantIssuedTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-07-01</xbrli:startDate>

      <xbrli:endDate>2007-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bcli:RelatedPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To01_31_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2010To02_28_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>

      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2010To02_28_2010_InvestorOneMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:InvestorOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>

      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2010To02_28_2010_InvestorTwoMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:InvestorTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>

      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2010To02_28_2010_InvestorThreeMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:InvestorThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>

      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2011To02_28_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>

      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="invest:InvestmentAxis">bcli:InvestmentAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>

      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="invest:InvestmentAxis">bcli:InvestmentAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bcli:WarrantIssuedOneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="invest:InvestmentAxis">bcli:InvestmentAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>

      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedTwoMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="invest:InvestmentAxis">bcli:InvestmentAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bcli:WarrantIssuedTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>

      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2011To02_28_2011_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>

      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2011To02_28_2011_CashMemberusgaapCashAndCashEquivalentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>

      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2011To03_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>

      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2011To03_31_2011_CashMemberusgaapCashAndCashEquivalentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>

      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcli:PublicOfferingMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcli:PublicOfferingMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To07_31_2012_PlacementAgentMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:PlacementAgentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To07_17_2012_LeaderUnderwriters1993LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bcli:LeaderUnderwriters1993LtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-07-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2013To02_28_2013_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-02-01</xbrli:startDate>

      <xbrli:endDate>2013-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2004To12_31_2004_GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005MemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-01-01</xbrli:startDate>

      <xbrli:endDate>2004-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2004To12_31_2004_GlobalShareOptionPlan2004MemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:GlobalShareOptionPlan2004Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-01-01</xbrli:startDate>

      <xbrli:endDate>2004-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2004To12_31_2004_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:USStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-01-01</xbrli:startDate>

      <xbrli:endDate>2004-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2008To12_31_2008_GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005MemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>

      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005MemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005MemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2005To12_31_2009_DirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-01-01</xbrli:startDate>

      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2006To06_30_2006_EmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>

      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2006To06_30_2006_EmployeeMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:EmployeeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>

      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2006To06_30_2006_EmployeeMemberusgaapTitleOfIndividualAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:EmployeeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>

      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2007To10_31_2007_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-10-01</xbrli:startDate>

      <xbrli:endDate>2007-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2008To11_30_2008_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-11-01</xbrli:startDate>

      <xbrli:endDate>2008-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2009To06_30_2009_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-06-01</xbrli:startDate>

      <xbrli:endDate>2009-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_25_2011_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-07-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2011To07_31_2011_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>

      <xbrli:endDate>2011-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2012To04_30_2012_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>

      <xbrli:endDate>2012-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2009To06_30_2009_FormerChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerChiefFinancialOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-06-01</xbrli:startDate>

      <xbrli:endDate>2009-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2010To04_30_2010_MrIsraeliMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:MrIsraeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-04-01</xbrli:startDate>

      <xbrli:endDate>2010-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2010To04_30_2010_HadasitMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:HadasitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-04-01</xbrli:startDate>

      <xbrli:endDate>2010-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2011To06_30_2011_MrIsraeliMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:MrIsraeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>

      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2012To04_30_2012_MrIsraeliMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:MrIsraeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>

      <xbrli:endDate>2012-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To04_30_2013_MrIsraeliMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:MrIsraeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2013-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2011To06_30_2011_HadasitMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:HadasitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>

      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2012To04_30_2012_HadasitMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:HadasitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>

      <xbrli:endDate>2012-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To04_30_2013_HadasitMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:HadasitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2013-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_MrIsraeliMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:MrIsraeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_HadasitMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:HadasitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2010To12_31_2010_DirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-12-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2010To12_31_2010_ScientificBoardMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ScientificBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-12-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To01_31_2011_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2011To06_30_2011_DirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>

      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2011To08_31_2011_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-08-01</xbrli:startDate>

      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2012To08_31_2012_DirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>

      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2012To08_31_2012_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>

      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To04_19_2013_DirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2013-04-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2006To04_30_2007_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-05-01</xbrli:startDate>

      <xbrli:endDate>2007-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2008To08_31_2008_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-08-01</xbrli:startDate>

      <xbrli:endDate>2008-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2010To12_31_2010_DirectorOneMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:DirectorOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-12-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2010To06_30_2010_ManagementMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-05-01</xbrli:startDate>

      <xbrli:endDate>2010-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2011To06_30_2011_DirectorOneMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:DirectorOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>

      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2011To06_30_2011_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>

      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2011To08_31_2011_MrSchorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:MrSchorMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-08-01</xbrli:startDate>

      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2011To08_31_2011_MrSchorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:MrSchorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-08-01</xbrli:startDate>

      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2011To08_31_2011_RestrictedStockMemberusgaapAwardTypeAxis_ScientificBoardMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ScientificBoardMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-08-01</xbrli:startDate>

      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2011To11_30_2011_BoardMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:BoardMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-11-01</xbrli:startDate>

      <xbrli:endDate>2011-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2011To11_30_2011_FormerDirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:FormerDirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-11-01</xbrli:startDate>

      <xbrli:endDate>2011-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2012To08_31_2012_ManagementMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>

      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To04_19_2013_ManagementMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2013-04-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_MinimumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_MaximumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_MinimumMemberusgaapRangeAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bcli:WarrantIssuedOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_MaximumMemberusgaapRangeAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bcli:WarrantIssuedOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2004To06_30_2004_FilingServiceMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:FilingServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-06-01</xbrli:startDate>

      <xbrli:endDate>2004-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2005To02_28_2005_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:USStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-02-01</xbrli:startDate>

      <xbrli:endDate>2005-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2005To04_30_2005_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:USStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-03-01</xbrli:startDate>

      <xbrli:endDate>2005-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2004To06_30_2004_FilingServiceMemberusgaapProductOrServiceAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:FilingServiceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-06-01</xbrli:startDate>

      <xbrli:endDate>2004-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2004To06_30_2004_FilingServiceMemberusgaapProductOrServiceAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:FilingServiceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-06-01</xbrli:startDate>

      <xbrli:endDate>2004-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2005To04_30_2005_ScientificAdvisoryBoardOneMemberusgaapProductOrServiceAxis_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ScientificAdvisoryBoardOneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:USStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-03-01</xbrli:startDate>

      <xbrli:endDate>2005-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2005To04_30_2005_ScientificAdvisoryBoardTwoMemberusgaapProductOrServiceAxis_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ScientificAdvisoryBoardTwoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:USStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-03-01</xbrli:startDate>

      <xbrli:endDate>2005-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2005To04_30_2005_ScientificAdvisoryBoardThreeMemberusgaapProductOrServiceAxis_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ScientificAdvisoryBoardThreeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:USStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-03-01</xbrli:startDate>

      <xbrli:endDate>2005-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2005To04_30_2005_ScientificAdvisoryBoardFourMemberusgaapProductOrServiceAxis_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">bcli:USStockOptionAndIncentivePlanMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ScientificAdvisoryBoardFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-03-01</xbrli:startDate>

      <xbrli:endDate>2005-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2005To12_31_2009_ServiceProviderMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ServiceProviderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-01-01</xbrli:startDate>

      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_05_2007_ConvertiblePromissoryNoteToThirdPartyMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ConvertiblePromissoryNoteToThirdPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-03-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2008To05_20_2008_FinancialAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:FinancialAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-05-01</xbrli:startDate>

      <xbrli:endDate>2008-05-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_27_2010_ConvertiblePromissoryNoteToThirdPartyMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ConvertiblePromissoryNoteToThirdPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-01-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To01_27_2010_ConvertiblePromissoryNoteToThirdPartyMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ConvertiblePromissoryNoteToThirdPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-01-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2007To10_31_2007_ScientificAdvisoryBoardMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-10-01</xbrli:startDate>

      <xbrli:endDate>2007-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2009To04_30_2009_ChiefTechnologyAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ChiefTechnologyAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-04-01</xbrli:startDate>

      <xbrli:endDate>2009-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2009To10_31_2009_ServiceProviderMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ServiceProviderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>

      <xbrli:endDate>2009-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2009To10_31_2009_ServiceProviderOneMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ServiceProviderOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>

      <xbrli:endDate>2009-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_13_2009_ConvertiblePromissoryNoteToLegalAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ConvertiblePromissoryNoteToLegalAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-12-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To01_31_2010_PublicRelationsAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:PublicRelationsAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To01_31_2010_ServiceProviderMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ServiceProviderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2010To02_28_2010_LegalAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:LegalAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>

      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2010To04_30_2010_ProfMelamedMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:ProfMelamedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-04-01</xbrli:startDate>

      <xbrli:endDate>2010-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2010To05_31_2010_PublicRelationsAdvisorMemberusgaapProductOrServiceAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:PublicRelationsAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-05-01</xbrli:startDate>

      <xbrli:endDate>2010-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2010To12_31_2010_ServiceProviderMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ServiceProviderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-12-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2010To12_31_2010_ConsultantsMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-12-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2011To02_28_2011_LegalAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:LegalAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>

      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2011To06_30_2011_LegalAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:LegalAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>

      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2011To06_30_2011_ConsultantsMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>

      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2011To06_30_2011_ServiceProviderMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ServiceProviderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>

      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_HadasitMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcli:HadasitMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_EnrollmentOfOneThirdOfPatientsMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcli:EnrollmentOfOneThirdOfPatientsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_EnrollmentOfAllPatientsMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcli:EnrollmentOfAllPatientsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_CompletionOfStudyMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcli:CompletionOfStudyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To01_31_2013_ConsultantsMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2013To02_28_2013_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-02-01</xbrli:startDate>

      <xbrli:endDate>2013-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2013To03_31_2013_LegalAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:LegalAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-03-01</xbrli:startDate>

      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_LegalAdvisorMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:LegalAdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2013To03_31_2013_ServiceProviderMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ServiceProviderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-03-01</xbrli:startDate>

      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ServiceProviderMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcli:ServiceProviderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2013To08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcli:PublicOfferingMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>

      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcli:PublicOfferingMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateNovDec2004Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFebDec2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFebDec2006Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateMar2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApr2008Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateAprOct2009Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateJan2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJan2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFeb2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFeb2010OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2010OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFeb2010TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2010TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateApr2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApr2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateJan2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJan2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFeb2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2011OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFeb2011TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2011TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateApr2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApr2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateApril2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApril2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateJuly2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJuly2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateJuly2012OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJuly2012OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateJuly2012TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJuly2012TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateFeb2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateApril2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApril2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_IssuanceDateAugust2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateAugust2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateNovDec2004Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFebDec2005Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFebDec2006Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateMar2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApr2008Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateAprOct2009Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateJan2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJan2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFeb2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFeb2010OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2010OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFeb2010TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2010TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateApr2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApr2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateJan2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJan2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFeb2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2011OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFeb2011TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2011TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateApr2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApr2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateApril2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApril2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateJuly2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJuly2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateJuly2012OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJuly2012OneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateJuly2012TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateJuly2012TwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateFeb2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateFeb2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateApril2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateApril2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_IssuanceDateAugust2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">bcli:IssuanceDateAugust2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_InterestExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bcli:InterestExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To09_30_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To09_30_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To09_30_2013_InterestExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bcli:InterestExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_InterestExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bcli:InterestExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012_InterestExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bcli:InterestExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To09_30_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To09_30_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_23_2000To09_30_2013_InterestExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bcli:InterestExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2000-09-23</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-04-01</xbrli:startDate>

      <xbrli:endDate>2005-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2004To03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-04-01</xbrli:startDate>

      <xbrli:endDate>2005-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-04-01</xbrli:startDate>

      <xbrli:endDate>2005-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2004-04-01</xbrli:startDate>

      <xbrli:endDate>2005-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2005-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2005-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2005-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2005-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-04-01</xbrli:startDate>

      <xbrli:endDate>2006-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-04-01</xbrli:startDate>

      <xbrli:endDate>2006-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-04-01</xbrli:startDate>

      <xbrli:endDate>2006-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2005-04-01</xbrli:startDate>

      <xbrli:endDate>2006-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-04-01</xbrli:startDate>

      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-04-01</xbrli:startDate>

      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-04-01</xbrli:startDate>

      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2006-04-01</xbrli:startDate>

      <xbrli:endDate>2006-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>

      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>

      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>

      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>

      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>

      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>

      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>

      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>

      <xbrli:endDate>2008-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>

      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2009To12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>

      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2009To12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>

      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2009To12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-01-01</xbrli:startDate>

      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>

      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2013To09_30_2013" id="Factid_1">10-Q</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2013To09_30_2013" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2013To09_30_2013" id="Factid_3">2013-09-30</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2013To09_30_2013" id="Factid_4">2013</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2013To09_30_2013" id="Factid_5">Q3</dei:DocumentFiscalPeriodFocus>

  <dei:TradingSymbol contextRef="P01_01_2013To09_30_2013" id="Factid_6">BCLI</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn11_12_2013" id="Factid_7" unitRef="shares" decimals="INF">176263587</dei:EntityCommonStockSharesOutstanding>

  <dei:EntityRegistrantName contextRef="P01_01_2013To09_30_2013" id="Factid_8">BRAINSTORM CELL THERAPEUTICS INC.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2013To09_30_2013" id="Factid_9">0001137883</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2013To09_30_2013" id="Factid_10">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityFilerCategory contextRef="P01_01_2013To09_30_2013" id="Factid_11">Smaller Reporting Company</dei:EntityFilerCategory>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn09_30_2013" id="Factid_12" unitRef="USD_per_Share" decimals="5">0.00005</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2012" id="Factid_13" unitRef="USD_per_Share" decimals="5">0.00005</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn09_30_2013" id="Factid_14" unitRef="shares" decimals="INF">800000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2012" id="Factid_15" unitRef="shares" decimals="INF">800000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn09_30_2013" id="Factid_16" unitRef="shares" decimals="INF">176243587</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn09_30_2013" id="Factid_17" unitRef="shares" decimals="INF">176243587</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2012" id="Factid_18" unitRef="shares" decimals="INF">150085035</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2012" id="Factid_19" unitRef="shares" decimals="INF">150085035</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn09_30_2013" id="Factid_20" unitRef="USD" decimals="-3">329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2012" id="Factid_21" unitRef="USD" decimals="-3">1317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:ShortTermInvestments contextRef="PAsOn09_30_2013" id="Factid_22" unitRef="USD" decimals="-3">4786000</us-gaap:ShortTermInvestments>

  <us-gaap:ShortTermInvestments contextRef="PAsOn12_31_2012" id="Factid_23" unitRef="USD" decimals="-3">2769000</us-gaap:ShortTermInvestments>

  <us-gaap:NontradeReceivablesCurrent contextRef="PAsOn09_30_2013" id="Factid_24" unitRef="USD" decimals="-3">502000</us-gaap:NontradeReceivablesCurrent>

  <us-gaap:NontradeReceivablesCurrent contextRef="PAsOn12_31_2012" id="Factid_25" unitRef="USD" decimals="-3">742000</us-gaap:NontradeReceivablesCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn09_30_2013" id="Factid_26" unitRef="USD" decimals="-3">55000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2012" id="Factid_27" unitRef="USD" decimals="-3">46000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn09_30_2013" id="Factid_28" unitRef="USD" decimals="-3">5672000</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2012" id="Factid_29" unitRef="USD" decimals="-3">4874000</us-gaap:AssetsCurrent>

  <us-gaap:PrepaidExpenseNoncurrent contextRef="PAsOn09_30_2013" id="Factid_30" unitRef="USD" decimals="-3">28000</us-gaap:PrepaidExpenseNoncurrent>

  <us-gaap:PrepaidExpenseNoncurrent contextRef="PAsOn12_31_2012" id="Factid_31" unitRef="USD" decimals="-3">17000</us-gaap:PrepaidExpenseNoncurrent>

  <bcli:SeverancePayFund contextRef="PAsOn09_30_2013" id="Factid_32" unitRef="USD" decimals="-3">245000</bcli:SeverancePayFund>

  <bcli:SeverancePayFund contextRef="PAsOn12_31_2012" id="Factid_33" unitRef="USD" decimals="-3">172000</bcli:SeverancePayFund>

  <us-gaap:LongTermInvestments contextRef="PAsOn09_30_2013" id="Factid_34" unitRef="USD" decimals="-3">273000</us-gaap:LongTermInvestments>

  <us-gaap:LongTermInvestments contextRef="PAsOn12_31_2012" id="Factid_35" unitRef="USD" decimals="-3">189000</us-gaap:LongTermInvestments>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn09_30_2013" id="Factid_36" unitRef="USD" decimals="-3">267000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2012" id="Factid_37" unitRef="USD" decimals="-3">247000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:Assets contextRef="PAsOn09_30_2013" id="Factid_38" unitRef="USD" decimals="-3">6212000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2012" id="Factid_39" unitRef="USD" decimals="-3">5310000</us-gaap:Assets>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn09_30_2013" id="Factid_40" unitRef="USD" decimals="-3">446000</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn12_31_2012" id="Factid_41" unitRef="USD" decimals="-3">358000</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn09_30_2013" id="Factid_42" unitRef="USD" decimals="-3">710000</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn12_31_2012" id="Factid_43" unitRef="USD" decimals="-3">605000</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:AccountsPayableOtherCurrent contextRef="PAsOn09_30_2013" id="Factid_44" unitRef="USD" decimals="-3">230000</us-gaap:AccountsPayableOtherCurrent>

  <us-gaap:AccountsPayableOtherCurrent contextRef="PAsOn12_31_2012" id="Factid_45" unitRef="USD" decimals="-3">176000</us-gaap:AccountsPayableOtherCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn09_30_2013" id="Factid_46" unitRef="USD" decimals="-3">1386000</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2012" id="Factid_47" unitRef="USD" decimals="-3">1139000</us-gaap:LiabilitiesCurrent>

  <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent contextRef="PAsOn09_30_2013" id="Factid_48" unitRef="USD" decimals="-3">291000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>

  <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent contextRef="PAsOn12_31_2012" id="Factid_49" unitRef="USD" decimals="-3">189000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>

  <us-gaap:Liabilities contextRef="PAsOn09_30_2013" id="Factid_50" unitRef="USD" decimals="-3">1677000</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2012" id="Factid_51" unitRef="USD" decimals="-3">1328000</us-gaap:Liabilities>

  <us-gaap:CommonStockValue contextRef="PAsOn09_30_2013" id="Factid_52" unitRef="USD" decimals="-3">8000</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2012" id="Factid_53" unitRef="USD" decimals="-3">7000</us-gaap:CommonStockValue>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn09_30_2013" id="Factid_54" unitRef="USD" decimals="-3">55717000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn12_31_2012" id="Factid_55" unitRef="USD" decimals="-3">51483000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="PAsOn09_30_2013" id="Factid_56" unitRef="USD" decimals="-3">51190000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>

  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="PAsOn12_31_2012" id="Factid_57" unitRef="USD" decimals="-3">47508000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2013" id="Factid_58" unitRef="USD" decimals="-3">4535000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012" id="Factid_59" unitRef="USD" decimals="-3">3982000</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn09_30_2013" id="Factid_60" unitRef="USD" decimals="-3">6212000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2012" id="Factid_61" unitRef="USD" decimals="-3">5310000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2013To09_30_2013" id="Factid_62" unitRef="USD" decimals="-3">2068000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2012To09_30_2012" id="Factid_63" unitRef="USD" decimals="-3">1486000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2013To09_30_2013" id="Factid_64" unitRef="USD" decimals="-3">804000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2012To09_30_2012" id="Factid_65" unitRef="USD" decimals="-3">732000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P09_23_2000To09_30_2013" id="Factid_66" unitRef="USD" decimals="-3">28257000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2013To09_30_2013" id="Factid_67" unitRef="USD" decimals="-3">1574000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2012To09_30_2012" id="Factid_68" unitRef="USD" decimals="-3">1397000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_01_2013To09_30_2013" id="Factid_69" unitRef="USD" decimals="-3">272000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_01_2012To09_30_2012" id="Factid_70" unitRef="USD" decimals="-3">440000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P09_23_2000To09_30_2013" id="Factid_71" unitRef="USD" decimals="-3">20325000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:OperatingExpenses contextRef="P01_01_2013To09_30_2013" id="Factid_72" unitRef="USD" decimals="-3">3642000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2012To09_30_2012" id="Factid_73" unitRef="USD" decimals="-3">2883000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P07_01_2013To09_30_2013" id="Factid_74" unitRef="USD" decimals="-3">1076000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P07_01_2012To09_30_2012" id="Factid_75" unitRef="USD" decimals="-3">1172000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P09_23_2000To09_30_2013" id="Factid_76" unitRef="USD" decimals="-3">48582000</us-gaap:OperatingExpenses>

  <bcli:FinancialExpensesIncomeNet contextRef="P01_01_2013To09_30_2013" id="Factid_77" unitRef="USD" decimals="-3">21000</bcli:FinancialExpensesIncomeNet>

  <bcli:FinancialExpensesIncomeNet contextRef="P01_01_2012To09_30_2012" id="Factid_78" unitRef="USD" decimals="-3">-37000</bcli:FinancialExpensesIncomeNet>

  <bcli:FinancialExpensesIncomeNet contextRef="P07_01_2013To09_30_2013" id="Factid_79" unitRef="USD" decimals="-3">5000</bcli:FinancialExpensesIncomeNet>

  <bcli:FinancialExpensesIncomeNet contextRef="P07_01_2012To09_30_2012" id="Factid_80" unitRef="USD" decimals="-3">-22000</bcli:FinancialExpensesIncomeNet>

  <bcli:FinancialExpensesIncomeNet contextRef="P09_23_2000To09_30_2013" id="Factid_81" unitRef="USD" decimals="-3">2475000</bcli:FinancialExpensesIncomeNet>

  <us-gaap:OtherNonoperatingIncome contextRef="P01_01_2013To09_30_2013" id="Factid_82" unitRef="USD" decimals="-3">0</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OtherNonoperatingIncome contextRef="P01_01_2012To09_30_2012" id="Factid_83" unitRef="USD" decimals="-3">0</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OtherNonoperatingIncome contextRef="P07_01_2013To09_30_2013" id="Factid_84" unitRef="USD" decimals="-3">0</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OtherNonoperatingIncome contextRef="P07_01_2012To09_30_2012" id="Factid_85" unitRef="USD" decimals="-3">0</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OtherNonoperatingIncome contextRef="P09_23_2000To09_30_2013" id="Factid_86" unitRef="USD" decimals="-3">132000</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2013To09_30_2013" id="Factid_87" unitRef="USD" decimals="-3">-3663000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2012To09_30_2012" id="Factid_88" unitRef="USD" decimals="-3">-2846000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P07_01_2013To09_30_2013" id="Factid_89" unitRef="USD" decimals="-3">-1081000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P07_01_2012To09_30_2012" id="Factid_90" unitRef="USD" decimals="-3">-1150000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P09_23_2000To09_30_2013" id="Factid_91" unitRef="USD" decimals="-3">-50925000</us-gaap:OperatingIncomeLoss>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2013To09_30_2013" id="Factid_92" unitRef="USD" decimals="-3">19000</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2012To09_30_2012" id="Factid_93" unitRef="USD" decimals="-3">5000</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P07_01_2013To09_30_2013" id="Factid_94" unitRef="USD" decimals="-3">1000</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P07_01_2012To09_30_2012" id="Factid_95" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P09_23_2000To09_30_2013" id="Factid_96" unitRef="USD" decimals="-3">101000</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2013To09_30_2013" id="Factid_97" unitRef="USD" decimals="-3">-3682000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2012To09_30_2012" id="Factid_98" unitRef="USD" decimals="-3">-2851000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P07_01_2013To09_30_2013" id="Factid_99" unitRef="USD" decimals="-3">-1082000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P07_01_2012To09_30_2012" id="Factid_100" unitRef="USD" decimals="-3">-1150000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P09_23_2000To09_30_2013" id="Factid_101" unitRef="USD" decimals="-3">-51026000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2013To09_30_2013" id="Factid_102" unitRef="USD" decimals="-3">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2012To09_30_2012" id="Factid_103" unitRef="USD" decimals="-3">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P07_01_2013To09_30_2013" id="Factid_104" unitRef="USD" decimals="-3">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P07_01_2012To09_30_2012" id="Factid_105" unitRef="USD" decimals="-3">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P09_23_2000To09_30_2013" id="Factid_106" unitRef="USD" decimals="-3">-164000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2013To09_30_2013" id="Factid_107" unitRef="USD_per_Share" decimals="2">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2012To09_30_2012" id="Factid_108" unitRef="USD_per_Share" decimals="2">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P07_01_2013To09_30_2013" id="Factid_109" unitRef="USD_per_Share" decimals="2">-0.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P07_01_2012To09_30_2012" id="Factid_110" unitRef="USD_per_Share" decimals="2">-0.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To09_30_2013" id="Factid_111" unitRef="USD" decimals="-3">-3682000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To09_30_2012" id="Factid_112" unitRef="USD" decimals="-3">-2851000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2013To09_30_2013" id="Factid_113" unitRef="USD" decimals="-3">-1082000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2012To09_30_2012" id="Factid_114" unitRef="USD" decimals="-3">-1150000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P09_23_2000To09_30_2013" id="Factid_115" unitRef="USD" decimals="-3">-51190000</us-gaap:NetIncomeLoss>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2013To09_30_2013" id="Factid_116" unitRef="shares" decimals="INF">152094266</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2012To09_30_2012" id="Factid_117" unitRef="shares" decimals="INF">133403123</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_01_2013To09_30_2013" id="Factid_118" unitRef="shares" decimals="INF">164223127</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_01_2012To09_30_2012" id="Factid_119" unitRef="shares" decimals="INF">145407840</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <bcli:StockIssuedDuringPeriodForCashInSeptemberPricePerShare contextRef="P09_23_2000To03_31_2001" id="Factid_120" unitRef="USD_per_Share" decimals="5">0.00188</bcli:StockIssuedDuringPeriodForCashInSeptemberPricePerShare>

  <bcli:StockIssuedDuringPeriodForCashInMarchPricePerShare contextRef="P09_23_2000To03_31_2001" id="Factid_121" unitRef="USD_per_Share" decimals="4">0.0375</bcli:StockIssuedDuringPeriodForCashInMarchPricePerShare>

  <bcli:PricePerShareOfStockIssuedDuringPeriodToPurchaseMineralOption contextRef="P04_01_2003To03_31_2004" id="Factid_122" unitRef="USD_per_Share" decimals="3">0.065</bcli:PricePerShareOfStockIssuedDuringPeriodToPurchaseMineralOption>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_22_2000" id="Factid_123" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_22_2000_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_124" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_22_2000_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_125" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_22_2000_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_126" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_22_2000_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_127" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn09_22_2000_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_128" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <bcli:StockIssuedDuringPeriodForCashInSeptember contextRef="P09_23_2000To03_31_2001" id="Factid_129" unitRef="USD" decimals="-3">17000</bcli:StockIssuedDuringPeriodForCashInSeptember>

  <bcli:StockIssuedDuringPeriodForCashInSeptember contextRef="P09_23_2000To03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_130" unitRef="USD" decimals="-3">1000</bcli:StockIssuedDuringPeriodForCashInSeptember>

  <bcli:StockIssuedDuringPeriodForCashInSeptember contextRef="P09_23_2000To03_31_2001_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_131" unitRef="USD" decimals="-3">16000</bcli:StockIssuedDuringPeriodForCashInSeptember>

  <bcli:StockIssuedDuringPeriodForCashInSeptember contextRef="P09_23_2000To03_31_2001_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_132" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForCashInSeptember>

  <bcli:StockIssuedDuringPeriodForCashInSeptember contextRef="P09_23_2000To03_31_2001_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_133" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForCashInSeptember>

  <bcli:StockIssuedDuringPeriodForCashSharesInSeptember contextRef="P09_23_2000To03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_134" unitRef="shares" decimals="INF">8500000</bcli:StockIssuedDuringPeriodForCashSharesInSeptember>

  <bcli:StockIssuedDuringPeriodForCashInMarch contextRef="P09_23_2000To03_31_2001" id="Factid_135" unitRef="USD" decimals="-3">60000</bcli:StockIssuedDuringPeriodForCashInMarch>

  <bcli:StockIssuedDuringPeriodForCashInMarch contextRef="P09_23_2000To03_31_2001_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_136" unitRef="USD" decimals="-3">60000</bcli:StockIssuedDuringPeriodForCashInMarch>

  <bcli:StockIssuedDuringPeriodForCashInMarch contextRef="P09_23_2000To03_31_2001_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_137" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForCashInMarch>

  <bcli:StockIssuedDuringPeriodForCashInMarch contextRef="P09_23_2000To03_31_2001_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_138" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForCashInMarch>

  <bcli:StockIssuedDuringPeriodForCashSharesInMarch contextRef="P09_23_2000To03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_139" unitRef="shares" decimals="INF">1600000</bcli:StockIssuedDuringPeriodForCashSharesInMarch>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P09_23_2000To03_31_2001" id="Factid_140" unitRef="USD" decimals="-3">8000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P09_23_2000To03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_141" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P09_23_2000To03_31_2001_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_142" unitRef="USD" decimals="-3">8000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P09_23_2000To03_31_2001_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_143" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P09_23_2000To03_31_2001_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_144" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <us-gaap:NetIncomeLoss contextRef="P09_23_2000To03_31_2001" id="Factid_145" unitRef="USD" decimals="-3">-17000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P09_23_2000To03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_146" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P09_23_2000To03_31_2001_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_147" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P09_23_2000To03_31_2001_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_148" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P09_23_2000To03_31_2001_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_149" unitRef="USD" decimals="-3">-17000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2001" id="Factid_150" unitRef="USD" decimals="-3">68000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_151" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2001_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_152" unitRef="USD" decimals="-3">84000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2001_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_153" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2001_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_154" unitRef="USD" decimals="-3">-17000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_155" unitRef="shares" decimals="INF">10100000</us-gaap:SharesOutstanding>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2001To03_31_2002" id="Factid_156" unitRef="USD" decimals="-3">11000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2001To03_31_2002_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_157" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2001To03_31_2002_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_158" unitRef="USD" decimals="-3">11000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2001To03_31_2002_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_159" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2001To03_31_2002_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_160" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2001To03_31_2002" id="Factid_161" unitRef="USD" decimals="-3">-26000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2001To03_31_2002_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_162" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2001To03_31_2002_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_163" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2001To03_31_2002_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_164" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2001To03_31_2002_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_165" unitRef="USD" decimals="-3">-26000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2002" id="Factid_166" unitRef="USD" decimals="-3">53000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2002_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_167" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2002_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_168" unitRef="USD" decimals="-3">95000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2002_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_169" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2002_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_170" unitRef="USD" decimals="-3">-43000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2002_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_171" unitRef="shares" decimals="INF">10100000</us-gaap:SharesOutstanding>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2002To03_31_2003" id="Factid_172" unitRef="USD" decimals="-3">15000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2002To03_31_2003_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_173" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2002To03_31_2003_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_174" unitRef="USD" decimals="-3">15000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2002To03_31_2003_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_175" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2002To03_31_2003_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_176" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2002To03_31_2003" id="Factid_177" unitRef="USD" decimals="-3">-47000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2002To03_31_2003_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_178" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2002To03_31_2003_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_179" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2002To03_31_2003_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_180" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2002To03_31_2003_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_181" unitRef="USD" decimals="-3">-47000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2003" id="Factid_182" unitRef="USD" decimals="-3">21000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2003_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_183" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2003_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_184" unitRef="USD" decimals="-3">110000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2003_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_185" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2003_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_186" unitRef="USD" decimals="-3">-90000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2003_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_187" unitRef="shares" decimals="INF">10100000</us-gaap:SharesOutstanding>

  <bcli:StockIssuedDuringPeriodValueStockSplits contextRef="P04_01_2003To03_31_2004" id="Factid_188" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueStockSplits>

  <bcli:StockIssuedDuringPeriodValueStockSplits contextRef="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_189" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueStockSplits>

  <bcli:StockIssuedDuringPeriodValueStockSplits contextRef="P04_01_2003To03_31_2004_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_190" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueStockSplits>

  <bcli:StockIssuedDuringPeriodValueStockSplits contextRef="P04_01_2003To03_31_2004_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_191" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueStockSplits>

  <bcli:StockIssuedDuringPeriodValueStockSplits contextRef="P04_01_2003To03_31_2004_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_192" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueStockSplits>

  <us-gaap:StockIssuedDuringPeriodSharesStockSplits contextRef="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_193" unitRef="shares" decimals="INF">10100000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P04_01_2003To03_31_2004" id="Factid_194" unitRef="USD" decimals="-3">6000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_195" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P04_01_2003To03_31_2004_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_196" unitRef="USD" decimals="-3">6000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P04_01_2003To03_31_2004_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_197" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P04_01_2003To03_31_2004_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_198" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_199" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2003To03_31_2004" id="Factid_200" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_201" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2003To03_31_2004_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_202" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2003To03_31_2004_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_203" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2003To03_31_2004_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_204" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodShares contextRef="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_205" unitRef="shares" decimals="INF">10062000</bcli:StockCancelledDuringPeriodShares>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2003To03_31_2004" id="Factid_206" unitRef="USD" decimals="-3">15000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_207" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2003To03_31_2004_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_208" unitRef="USD" decimals="-3">15000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2003To03_31_2004_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_209" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2003To03_31_2004_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_210" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2003To03_31_2004" id="Factid_211" unitRef="USD" decimals="-3">-73000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2003To03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_212" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2003To03_31_2004_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_213" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2003To03_31_2004_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_214" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2003To03_31_2004_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_215" unitRef="USD" decimals="-3">-73000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2004" id="Factid_216" unitRef="USD" decimals="-3">-31000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_217" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2004_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_218" unitRef="USD" decimals="-3">131000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2004_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_219" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2004_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_220" unitRef="USD" decimals="-3">-163000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2004_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_221" unitRef="shares" decimals="INF">10238000</us-gaap:SharesOutstanding>

  <bcli:StockIssuedDuringPeriodForCashInMarch contextRef="P09_23_2000To03_31_2001_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_222" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForCashInMarch>

  <us-gaap:OtherDepreciationAndAmortization contextRef="P01_01_2013To09_30_2013" id="Factid_223" unitRef="USD" decimals="-3">77000</us-gaap:OtherDepreciationAndAmortization>

  <us-gaap:OtherDepreciationAndAmortization contextRef="P01_01_2012To09_30_2012" id="Factid_224" unitRef="USD" decimals="-3">116000</us-gaap:OtherDepreciationAndAmortization>

  <us-gaap:OtherDepreciationAndAmortization contextRef="P07_01_2013To09_30_2013" id="Factid_225" unitRef="USD" decimals="-3">27000</us-gaap:OtherDepreciationAndAmortization>

  <us-gaap:OtherDepreciationAndAmortization contextRef="P07_01_2012To09_30_2012" id="Factid_226" unitRef="USD" decimals="-3">40000</us-gaap:OtherDepreciationAndAmortization>

  <us-gaap:OtherDepreciationAndAmortization contextRef="P09_23_2000To09_30_2013" id="Factid_227" unitRef="USD" decimals="-3">1235000</us-gaap:OtherDepreciationAndAmortization>

  <us-gaap:SeveranceCosts1 contextRef="P01_01_2013To09_30_2013" id="Factid_228" unitRef="USD" decimals="-3">29000</us-gaap:SeveranceCosts1>

  <us-gaap:SeveranceCosts1 contextRef="P01_01_2012To09_30_2012" id="Factid_229" unitRef="USD" decimals="-3">6000</us-gaap:SeveranceCosts1>

  <us-gaap:SeveranceCosts1 contextRef="P07_01_2013To09_30_2013" id="Factid_230" unitRef="USD" decimals="-3">22000</us-gaap:SeveranceCosts1>

  <us-gaap:SeveranceCosts1 contextRef="P07_01_2012To09_30_2012" id="Factid_231" unitRef="USD" decimals="-3">5000</us-gaap:SeveranceCosts1>

  <us-gaap:SeveranceCosts1 contextRef="P09_23_2000To09_30_2013" id="Factid_232" unitRef="USD" decimals="-3">46000</us-gaap:SeveranceCosts1>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P01_01_2013To09_30_2013" id="Factid_233" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P01_01_2012To09_30_2012" id="Factid_234" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P07_01_2013To09_30_2013" id="Factid_235" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P07_01_2012To09_30_2012" id="Factid_236" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P09_23_2000To09_30_2013" id="Factid_237" unitRef="USD" decimals="-3">451000</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P01_01_2013To09_30_2013" id="Factid_238" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P01_01_2012To09_30_2012" id="Factid_239" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P07_01_2012To09_30_2012" id="Factid_240" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P09_23_2000To09_30_2013" id="Factid_241" unitRef="USD" decimals="-3">1864000</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="P01_01_2013To09_30_2013" id="Factid_242" unitRef="USD" decimals="-3">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>

  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="P01_01_2012To09_30_2012" id="Factid_243" unitRef="USD" decimals="-3">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>

  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="P07_01_2013To09_30_2013" id="Factid_244" unitRef="USD" decimals="-3">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>

  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="P07_01_2012To09_30_2012" id="Factid_245" unitRef="USD" decimals="-3">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>

  <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="P09_23_2000To09_30_2013" id="Factid_246" unitRef="USD" decimals="-3">795000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>

  <bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders contextRef="P01_01_2013To09_30_2013" id="Factid_247" unitRef="USD" decimals="-3">213000</bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders>

  <bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders contextRef="P01_01_2012To09_30_2012" id="Factid_248" unitRef="USD" decimals="-3">46000</bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders>

  <bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders contextRef="P07_01_2013To09_30_2013" id="Factid_249" unitRef="USD" decimals="-3">11000</bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders>

  <bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders contextRef="P07_01_2012To09_30_2012" id="Factid_250" unitRef="USD" decimals="-3">38000</bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders>

  <bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders contextRef="P09_23_2000To09_30_2013" id="Factid_251" unitRef="USD" decimals="-3">21894000</bcli:ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders>

  <us-gaap:StockOptionPlanExpense contextRef="P01_01_2013To09_30_2013" id="Factid_252" unitRef="USD" decimals="-3">439000</us-gaap:StockOptionPlanExpense>

  <us-gaap:StockOptionPlanExpense contextRef="P01_01_2012To09_30_2012" id="Factid_253" unitRef="USD" decimals="-3">440000</us-gaap:StockOptionPlanExpense>

  <us-gaap:StockOptionPlanExpense contextRef="P07_01_2013To09_30_2013" id="Factid_254" unitRef="USD" decimals="-3">-75000</us-gaap:StockOptionPlanExpense>

  <us-gaap:StockOptionPlanExpense contextRef="P07_01_2012To09_30_2012" id="Factid_255" unitRef="USD" decimals="-3">127000</us-gaap:StockOptionPlanExpense>

  <us-gaap:StockOptionPlanExpense contextRef="P09_23_2000To09_30_2013" id="Factid_256" unitRef="USD" decimals="-3">7820000</us-gaap:StockOptionPlanExpense>

  <bcli:IncreaseInAccountsReceivableAndPrepaidExpenses contextRef="P01_01_2013To09_30_2013" id="Factid_257" unitRef="USD" decimals="-3">-231000</bcli:IncreaseInAccountsReceivableAndPrepaidExpenses>

  <bcli:IncreaseInAccountsReceivableAndPrepaidExpenses contextRef="P01_01_2012To09_30_2012" id="Factid_258" unitRef="USD" decimals="-3">121000</bcli:IncreaseInAccountsReceivableAndPrepaidExpenses>

  <bcli:IncreaseInAccountsReceivableAndPrepaidExpenses contextRef="P07_01_2013To09_30_2013" id="Factid_259" unitRef="USD" decimals="-3">-198000</bcli:IncreaseInAccountsReceivableAndPrepaidExpenses>

  <bcli:IncreaseInAccountsReceivableAndPrepaidExpenses contextRef="P07_01_2012To09_30_2012" id="Factid_260" unitRef="USD" decimals="-3">-56000</bcli:IncreaseInAccountsReceivableAndPrepaidExpenses>

  <bcli:IncreaseInAccountsReceivableAndPrepaidExpenses contextRef="P09_23_2000To09_30_2013" id="Factid_261" unitRef="USD" decimals="-3">557000</bcli:IncreaseInAccountsReceivableAndPrepaidExpenses>

  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="P01_01_2013To09_30_2013" id="Factid_262" unitRef="USD" decimals="-3">88000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>

  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="P01_01_2012To09_30_2012" id="Factid_263" unitRef="USD" decimals="-3">-50000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>

  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="P07_01_2013To09_30_2013" id="Factid_264" unitRef="USD" decimals="-3">73000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>

  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="P07_01_2012To09_30_2012" id="Factid_265" unitRef="USD" decimals="-3">-321000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>

  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="P09_23_2000To09_30_2013" id="Factid_266" unitRef="USD" decimals="-3">919000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2013To09_30_2013" id="Factid_267" unitRef="USD" decimals="-3">159000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2012To09_30_2012" id="Factid_268" unitRef="USD" decimals="-3">175000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P07_01_2013To09_30_2013" id="Factid_269" unitRef="USD" decimals="-3">113000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P07_01_2012To09_30_2012" id="Factid_270" unitRef="USD" decimals="-3">131000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P09_23_2000To09_30_2013" id="Factid_271" unitRef="USD" decimals="-3">1446000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <bcli:ErosionOfRestrictedCash contextRef="P01_01_2013To09_30_2013" id="Factid_272" unitRef="USD" decimals="-3">0</bcli:ErosionOfRestrictedCash>

  <bcli:ErosionOfRestrictedCash contextRef="P01_01_2012To09_30_2012" id="Factid_273" unitRef="USD" decimals="-3">0</bcli:ErosionOfRestrictedCash>

  <bcli:ErosionOfRestrictedCash contextRef="P07_01_2013To09_30_2013" id="Factid_274" unitRef="USD" decimals="-3">0</bcli:ErosionOfRestrictedCash>

  <bcli:ErosionOfRestrictedCash contextRef="P07_01_2012To09_30_2012" id="Factid_275" unitRef="USD" decimals="-3">0</bcli:ErosionOfRestrictedCash>

  <bcli:ErosionOfRestrictedCash contextRef="P09_23_2000To09_30_2013" id="Factid_276" unitRef="USD" decimals="-3">6000</bcli:ErosionOfRestrictedCash>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2013To09_30_2013" id="Factid_277" unitRef="USD" decimals="-3">-2446000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2012To09_30_2012" id="Factid_278" unitRef="USD" decimals="-3">-2239000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P07_01_2013To09_30_2013" id="Factid_279" unitRef="USD" decimals="-3">-713000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P07_01_2012To09_30_2012" id="Factid_280" unitRef="USD" decimals="-3">-1074000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P09_23_2000To09_30_2013" id="Factid_281" unitRef="USD" decimals="-3">-16709000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="P01_01_2013To09_30_2013" id="Factid_282" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="P01_01_2012To09_30_2012" id="Factid_283" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="P07_01_2013To09_30_2013" id="Factid_284" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="P07_01_2012To09_30_2012" id="Factid_285" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="P09_23_2000To09_30_2013" id="Factid_286" unitRef="USD" decimals="-3">-23000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2013To09_30_2013" id="Factid_287" unitRef="USD" decimals="-3">-2446000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2012To09_30_2012" id="Factid_288" unitRef="USD" decimals="-3">-2239000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P07_01_2013To09_30_2013" id="Factid_289" unitRef="USD" decimals="-3">-713000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P07_01_2012To09_30_2012" id="Factid_290" unitRef="USD" decimals="-3">-1074000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P09_23_2000To09_30_2013" id="Factid_291" unitRef="USD" decimals="-3">-16732000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2013To09_30_2013" id="Factid_292" unitRef="USD" decimals="-3">97000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2012To09_30_2012" id="Factid_293" unitRef="USD" decimals="-3">75000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P07_01_2013To09_30_2013" id="Factid_294" unitRef="USD" decimals="-3">31000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P09_23_2000To09_30_2013" id="Factid_295" unitRef="USD" decimals="-3">1320000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P01_01_2013To09_30_2013" id="Factid_296" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInRestrictedCash>

  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P01_01_2012To09_30_2012" id="Factid_297" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInRestrictedCash>

  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P07_01_2013To09_30_2013" id="Factid_298" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInRestrictedCash>

  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P09_23_2000To09_30_2013" id="Factid_299" unitRef="USD" decimals="-3">-6000</us-gaap:IncreaseDecreaseInRestrictedCash>

  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="P01_01_2013To09_30_2013" id="Factid_300" unitRef="USD" decimals="-3">2017000</us-gaap:PaymentsToAcquireShortTermInvestments>

  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="P01_01_2012To09_30_2012" id="Factid_301" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireShortTermInvestments>

  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="P07_01_2013To09_30_2013" id="Factid_302" unitRef="USD" decimals="-3">3006000</us-gaap:PaymentsToAcquireShortTermInvestments>

  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="P09_23_2000To09_30_2013" id="Factid_303" unitRef="USD" decimals="-3">4786000</us-gaap:PaymentsToAcquireShortTermInvestments>

  <bcli:InvestmentInLeaseDeposit contextRef="P01_01_2013To09_30_2013" id="Factid_304" unitRef="USD" decimals="-3">-11000</bcli:InvestmentInLeaseDeposit>

  <bcli:InvestmentInLeaseDeposit contextRef="P01_01_2012To09_30_2012" id="Factid_305" unitRef="USD" decimals="-3">0</bcli:InvestmentInLeaseDeposit>

  <bcli:InvestmentInLeaseDeposit contextRef="P07_01_2013To09_30_2013" id="Factid_306" unitRef="USD" decimals="-3">-2000</bcli:InvestmentInLeaseDeposit>

  <bcli:InvestmentInLeaseDeposit contextRef="P09_23_2000To09_30_2013" id="Factid_307" unitRef="USD" decimals="-3">-28000</bcli:InvestmentInLeaseDeposit>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2013To09_30_2013" id="Factid_308" unitRef="USD" decimals="-3">-2125000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2012To09_30_2012" id="Factid_309" unitRef="USD" decimals="-3">-75000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P07_01_2013To09_30_2013" id="Factid_310" unitRef="USD" decimals="-3">-3039000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P09_23_2000To09_30_2013" id="Factid_311" unitRef="USD" decimals="-3">-6128000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="P01_01_2013To09_30_2013" id="Factid_312" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="P01_01_2012To09_30_2012" id="Factid_313" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="P07_01_2013To09_30_2013" id="Factid_314" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="P09_23_2000To09_30_2013" id="Factid_315" unitRef="USD" decimals="-3">-16000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2013To09_30_2013" id="Factid_316" unitRef="USD" decimals="-3">-2125000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2012To09_30_2012" id="Factid_317" unitRef="USD" decimals="-3">-75000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P07_01_2013To09_30_2013" id="Factid_318" unitRef="USD" decimals="-3">-3039000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P09_23_2000To09_30_2013" id="Factid_319" unitRef="USD" decimals="-3">-6144000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P07_01_2012To09_30_2012" id="Factid_320" unitRef="USD" decimals="-3">14000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P07_01_2012To09_30_2012" id="Factid_321" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInRestrictedCash>

  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="P07_01_2012To09_30_2012" id="Factid_322" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireShortTermInvestments>

  <bcli:InvestmentInLeaseDeposit contextRef="P07_01_2012To09_30_2012" id="Factid_323" unitRef="USD" decimals="-3">0</bcli:InvestmentInLeaseDeposit>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P07_01_2012To09_30_2012" id="Factid_324" unitRef="USD" decimals="-3">-14000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="P07_01_2012To09_30_2012" id="Factid_325" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P07_01_2012To09_30_2012" id="Factid_326" unitRef="USD" decimals="-3">-14000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P01_01_2013To09_30_2013" id="Factid_327" unitRef="USD" decimals="-3">3576000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P01_01_2012To09_30_2012" id="Factid_328" unitRef="USD" decimals="-3">5028000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_01_2013To09_30_2013" id="Factid_329" unitRef="USD" decimals="-3">3326000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_01_2012To09_30_2012" id="Factid_330" unitRef="USD" decimals="-3">5028000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P09_23_2000To09_30_2013" id="Factid_331" unitRef="USD" decimals="-3">20918000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="P01_01_2013To09_30_2013" id="Factid_332" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>

  <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="P01_01_2012To09_30_2012" id="Factid_333" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>

  <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="P07_01_2013To09_30_2013" id="Factid_334" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>

  <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="P07_01_2012To09_30_2012" id="Factid_335" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>

  <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="P09_23_2000To09_30_2013" id="Factid_336" unitRef="USD" decimals="-3">2061000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P01_01_2013To09_30_2013" id="Factid_337" unitRef="USD" decimals="-3">7000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P01_01_2012To09_30_2012" id="Factid_338" unitRef="USD" decimals="-3">146000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P07_01_2013To09_30_2013" id="Factid_339" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P07_01_2012To09_30_2012" id="Factid_340" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P09_23_2000To09_30_2013" id="Factid_341" unitRef="USD" decimals="-3">784000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="P01_01_2013To09_30_2013" id="Factid_342" unitRef="USD" decimals="-3">0</us-gaap:RepaymentsOfOtherShortTermDebt>

  <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="P01_01_2012To09_30_2012" id="Factid_343" unitRef="USD" decimals="-3">0</us-gaap:RepaymentsOfOtherShortTermDebt>

  <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="P07_01_2013To09_30_2013" id="Factid_344" unitRef="USD" decimals="-3">0</us-gaap:RepaymentsOfOtherShortTermDebt>

  <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="P07_01_2012To09_30_2012" id="Factid_345" unitRef="USD" decimals="-3">0</us-gaap:RepaymentsOfOtherShortTermDebt>

  <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="P09_23_2000To09_30_2013" id="Factid_346" unitRef="USD" decimals="-3">601000</us-gaap:RepaymentsOfOtherShortTermDebt>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2013To09_30_2013" id="Factid_347" unitRef="USD" decimals="-3">3583000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2012To09_30_2012" id="Factid_348" unitRef="USD" decimals="-3">5174000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P07_01_2013To09_30_2013" id="Factid_349" unitRef="USD" decimals="-3">3326000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P07_01_2012To09_30_2012" id="Factid_350" unitRef="USD" decimals="-3">5028000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P09_23_2000To09_30_2013" id="Factid_351" unitRef="USD" decimals="-3">23162000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="P01_01_2013To09_30_2013" id="Factid_352" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="P01_01_2012To09_30_2012" id="Factid_353" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="P07_01_2013To09_30_2013" id="Factid_354" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="P07_01_2012To09_30_2012" id="Factid_355" unitRef="USD" decimals="-3">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="P09_23_2000To09_30_2013" id="Factid_356" unitRef="USD" decimals="-3">43000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2013To09_30_2013" id="Factid_357" unitRef="USD" decimals="-3">3583000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2012To09_30_2012" id="Factid_358" unitRef="USD" decimals="-3">5174000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P07_01_2013To09_30_2013" id="Factid_359" unitRef="USD" decimals="-3">3326000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P07_01_2012To09_30_2012" id="Factid_360" unitRef="USD" decimals="-3">5028000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P09_23_2000To09_30_2013" id="Factid_361" unitRef="USD" decimals="-3">23205000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2013To09_30_2013" id="Factid_362" unitRef="USD" decimals="-3">-988000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2012To09_30_2012" id="Factid_363" unitRef="USD" decimals="-3">2860000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P07_01_2013To09_30_2013" id="Factid_364" unitRef="USD" decimals="-3">-426000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P07_01_2012To09_30_2012" id="Factid_365" unitRef="USD" decimals="-3">3940000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P09_23_2000To09_30_2013" id="Factid_366" unitRef="USD" decimals="-3">329000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2011" id="Factid_367" unitRef="USD" decimals="-3">1923000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2013" id="Factid_368" unitRef="USD" decimals="-3">755000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2012" id="Factid_369" unitRef="USD" decimals="-3">843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn09_22_2000" id="Factid_370" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn09_30_2012" id="Factid_371" unitRef="USD" decimals="-3">4783000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P07_01_2013To09_30_2013" id="Factid_372" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfDebtDiscountPremium>

  <bcli:CommonStockTransferredAsPerPurchaseAgreement contextRef="PAsOn05_21_2004" id="Factid_373" unitRef="shares" decimals="INF">6880000</bcli:CommonStockTransferredAsPerPurchaseAgreement>

  <us-gaap:StockholdersEquityReverseStockSplit contextRef="P01_01_2013To09_30_2013" id="Factid_374">between 1-for-10 and 1-for-20</us-gaap:StockholdersEquityReverseStockSplit>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2012To07_31_2012" id="Factid_375" unitRef="USD" decimals="-5">5700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_01_2013To08_31_2013" id="Factid_376" unitRef="USD" decimals="-6">4000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn05_21_2004_PurchaseAgreementMemberusgaapStatementClassOfStockAxis" id="Factid_377" unitRef="shares" decimals="INF">10238000</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn05_21_2004_PurchaseAgreementMemberusgaapStatementClassOfStockAxis" id="Factid_378" unitRef="shares" decimals="INF">10238000</us-gaap:CommonStockSharesOutstanding>

  <bcli:GeneralAndGoingConcernDisclosureTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_379"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;NOTE 1&amp;#160;&amp;#160;-&amp;#160;&amp;#160;GENERAL&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; A.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;Brainstorm Cell Therapeutics Inc. (formerly: Golden Hand Resources Inc. - the "Company") was incorporated in the State of Washington on September 22, 2000.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; B.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On May 21, 2004, the former major stockholders of the Company entered into a purchase agreement with a group of private investors, who purchased from the former major stockholders &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,880,000&lt;/font&gt; shares of the then issued and outstanding &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,238,000&lt;/font&gt;&lt;/font&gt; shares of Common Stock.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; C.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On July 8, 2004, the Company entered into a licensing agreement with Ramot of Tel Aviv University Ltd. ("Ramot"), to acquire certain stem cell technology (see Note 4). Subsequent to this agreement, the Company decided to focus on the development of novel cell therapies for neurodegenerative diseases based on the acquired technology and research to be conducted and funded by the Company.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;Following the licensing agreement dated July 8, 2004, the management of the Company decided to abandon all old activities related to the sale of the digital data recorder product. The discontinuation of this activity was accounted for under the provision of Statement of Financial Accounting Standard ASC 360-10, "Accounting for the Impairment or Disposal of Long-Lived Assets".&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; D.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On October 25, 2004, the Company formed a wholly-owned subsidiary in Israel, Brainstorm Cell Therapeutics Ltd. ("BCT").&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; E.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On November 18, 2004, the Company changed its name from Golden Hand Resources Inc. to Brainstorm Cell Therapeutics Inc. to better reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. BCT, as defined above, owns all operational property and equipment.&lt;/font&gt;&lt;font style="FONT-FAMILY: Arial; FONT-SIZE: 10pt" dir="rtl"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;The Common Stock is registered and publicly traded on the OTC Markets Group service of the National Association of Securities Dealers, Inc. under the symbol BCLI.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt 85.05pt"&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; F.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On September 17, 2006, the Company changed the Company's fiscal year-end from March 31 to December 31.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; G.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;In December 2006, the Company changed its state of incorporation from Washington to Delaware.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; H.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;Since its inception, the Company has devoted substantially all of its efforts to research and development, recruiting management and technical staff, acquiring assets and raising capital. In addition, the Company has not generated revenues. Accordingly, the Company is considered to be in the development stage, as defined in "Accounting and reporting by development Stage Enterprises" ASC 915-10.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; I.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;In October 2010, the Israeli Ministry of Health (&amp;#8220;MOH&amp;#8221;) granted clearance for a Phase I/II clinical trial using the Company&amp;#8217;s autologous NurOwn stem cell therapy in patients with amyotrophic lateral sclerosis (&amp;#8221;ALS&amp;#8221;), subject to some additional process specifications as well as completion of the sterility validation study for tests performed.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On February 23, 2011, the Company submitted, to the MOH, all the required documents. Following approval of the MOH, a Phase I/II clinical study for ALS patients using the Company&amp;#8217;s autologous NurOwn stem cell therapy (the &amp;#8220;Clinical Trial&amp;#8221;) was initiated in June 2011.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;J&lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In February 2011, the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) granted orphan drug designation to the Company&amp;#8217;s NurOwn autologous adult stem cell product for the treatment of ALS.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -27pt; MARGIN: 0in 0in 0pt 85.5pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; K.&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On February 19, 2013, Brainstorm Ltd established a wholly-owned subsidiary, Brainstorm Cell&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Therapeutics UK Ltd. (&amp;#8220;Brainstorm UK&amp;#8221;). Brainstorm UK will act on behalf of the parent Company in the EU.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 85pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; L.&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On February 21, 2013, Brainstorm UK filed a request for Orphan Medicinal Product Designation by the European Medicine Agency (EMA) for its Autologous Bone Marrow derived Mesenchyme Stromal cells Secreting Neurotropic factors (MSC-NTF, NurOwn).&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 85pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; M.&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On April 8, 2013, the Company entered into an agreement with Dana-Farber Cancer Institute (&amp;#8220;Dana-Farber&amp;#8221;) to provide cGMP-compliant clean room facilities for production of the Company&amp;#8217;s NurOwn&amp;#153; stem cell candidate during its upcoming Phase II ALS trial in the United States. The Company&amp;#8217;s Phase II trial, to be launched in the second half of 2013 pending FDA approval, will be conducted at Massachusetts General Hospital (&amp;#8220;MGH&amp;#8221;), the University of Massachusetts (&amp;#8220;UMass&amp;#8221;) Hospital and the Mayo Clinic. The Connell and O'Reilly Cell Manipulation Core Facility at Dana-Farber will produce NurOwn for the MGH and UMass Hospital clinical sites.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 85pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; N.&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On April 18, 2013, the stockholders of the Company authorized the Board of Directors of the Company, in its discretion, should it deem it to be appropriate and in the best interests of the Company and its stockholders, to amend the Company&amp;#8217;s Certificate of Incorporation to effect a reverse stock split of the Company&amp;#8217;s issued and outstanding shares of common stock by a ratio of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;between 1-for-10 and 1-for-20&lt;/font&gt;, inclusive, without further approval or authorization of the Company&amp;#8217;s stockholders.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 85pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; O.&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On July 17, 2013, the European Commission granted Orphan Drug Designation to the Company&amp;#8217;s NurOwn autologous adult stem cell product for the treatment of ALS.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 85pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; P.&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On September 27, 2013, the Company recently completed treatment of the 12 patients in its ALS Phase IIa dose-escalating clinical trial with the Company&amp;#8217;s NurOwn&amp;#153; technology. The complete and final statistical analysis of the data is expected to be available after 6 months of follow up with the patients. The Company has been informed that one patient in the study expired due to a medical condition unrelated to the Clinical Trial.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 58.5pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="15%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Clinical Trial is being performed at Hadassah Medical Center in Jerusalem, Israel, under the direction of Prof. Dimitrios Karussis, M.D., Ph.D., head of Hadassah's Multiple Sclerosis Center and a member of the International Steering Committees for Bone Marrow and Mesenchymal Stem Cells Transplantation in Multiple Sclerosis (MS). The study is designed to establish the safety and preliminary efficacy of NurOwn at increasing dosages.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 56.7pt; unicode-bidi: embed; DIRECTION: ltr" align="left"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="left"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="left"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;GOING CONCERN:&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; As reflected in the accompanying financial statements, the Company&amp;#8217;s operations for the nine months ended September 30, 2013, resulted in a net loss of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,682&lt;/font&gt;. The Company&amp;#8217;s balance sheet reflects an accumulated deficit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;51,190&lt;/font&gt;. These conditions, together with the fact that the Company is a development stage Company and has no revenues nor are revenues expected in the near future, raise substantial doubt about the Company's ability to continue to operate as a going concern. The Company&amp;#8217;s ability to continue operating as a &amp;#8220;going concern&amp;#8221; is dependent on several factors, among them is its ability to raise sufficient additional working capital.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; In 2009, the Company decided to focus only on the effort to commence clinical trials for ALS and such trials did commence in 2011.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; In July 2012, the Company raised $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.7&lt;/font&gt; million, gross, in a public offering (See Note 6B (i)). In August 2013, the Company raised $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4&lt;/font&gt; million, gross, in a public offering (See Note 6B(j)). However, there can be no assurance that additional funds will be available on terms acceptable to the Company, or at all.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;These financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcli:GeneralAndGoingConcernDisclosureTextBlock>

  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_380"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="left"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;NOTE 2&amp;#160;-&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 90%; BACKGROUND-COLOR: transparent" valign="top" width="90%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" align="left"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div&gt;&lt;font size="2"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 90%; BACKGROUND-COLOR: transparent" valign="top" width="90%"&gt; &lt;div&gt;&lt;font size="2"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; LINE-HEIGHT: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 90%; BACKGROUND-COLOR: transparent" valign="top" width="90%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; LINE-HEIGHT: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: Times New Roman"&gt;&lt;font size="2"&gt;The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2012 are applied consistently in these financial statements.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>

  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_381"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;NOTE 3&amp;#160;-&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The accompanying unaudited interim financial statements have been prepared in a condensed format and include the consolidated financial operations of the Company and its wholly-owned subsidiary as of September 30, 2013 and for the three months then ended, in accordance with accounting principles generally accepted in the United States relating to the preparation of financial statements for interim periods. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013, are not necessarily indicative of the results that may be expected for the year ended December 31, 2013.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>

  <bcli:ResearchLicenseAgreementExpensesPaid contextRef="P12_01_2009To12_24_2009" id="Factid_382" unitRef="USD" decimals="-3">400000</bcli:ResearchLicenseAgreementExpensesPaid>

  <bcli:ObligationAmountToFundExtendedResearchPeriod contextRef="PAsOn12_31_2009" id="Factid_383" unitRef="USD" decimals="-3">1140000</bcli:ObligationAmountToFundExtendedResearchPeriod>

  <bcli:ResearchAndDevelopmentExpensesReversed contextRef="P01_01_2009To12_31_2009" id="Factid_384" unitRef="USD" decimals="-3">760000</bcli:ResearchAndDevelopmentExpensesReversed>

  <bcli:ResearchLicenseInterestRate contextRef="P01_01_2009To12_31_2009" id="Factid_385" unitRef="USD" decimals="-3">32000</bcli:ResearchLicenseInterestRate>

  <bcli:SharesGrantedAsPerResearchAndLicenseAgreement contextRef="P01_01_2009To12_31_2009" id="Factid_386" unitRef="shares" decimals="INF">1120000</bcli:SharesGrantedAsPerResearchAndLicenseAgreement>

  <bcli:NumberOfDaysOfRestrictionToSellSharesInOpenMarket contextRef="P01_01_2009To12_31_2009" id="Factid_387">P185D</bcli:NumberOfDaysOfRestrictionToSellSharesInOpenMarket>

  <bcli:StockBasedCompensationRelatedToSharesGrantedUnderResearchLicenseAgreement contextRef="P01_01_2009To12_31_2009" id="Factid_388" unitRef="USD" decimals="-3">51000</bcli:StockBasedCompensationRelatedToSharesGrantedUnderResearchLicenseAgreement>

  <bcli:NumberOfSharesSoldByPurchaserAsPermittedBySettlementAgreement contextRef="P01_01_2011To01_31_2011" id="Factid_389" unitRef="shares" decimals="INF">167530</bcli:NumberOfSharesSoldByPurchaserAsPermittedBySettlementAgreement>

  <bcli:ProceedsFromSharesSoldByPurchaserAsPermittedBySettlementAgreement contextRef="P01_01_2011To01_31_2011" id="Factid_390" unitRef="USD" decimals="-3">35000</bcli:ProceedsFromSharesSoldByPurchaserAsPermittedBySettlementAgreement>

  <bcli:TotalValueOfSharesSoldByPurchaser contextRef="P01_01_2011To01_31_2011" id="Factid_391" unitRef="USD" decimals="-3">235000</bcli:TotalValueOfSharesSoldByPurchaser>

  <bcli:ResearchLicensePaymentsMadeAsPerSettlementAgreement contextRef="P02_01_2011To02_28_2011" id="Factid_392" unitRef="USD" decimals="-3">5000</bcli:ResearchLicensePaymentsMadeAsPerSettlementAgreement>

  <bcli:PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus contextRef="P01_01_2013To09_30_2013" id="Factid_393" unitRef="pure" decimals="2">0.05</bcli:PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus>

  <bcli:PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus contextRef="P01_01_2013To09_30_2013" id="Factid_394" unitRef="pure" decimals="2">0.03</bcli:PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus>

  <bcli:ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus contextRef="P01_01_2013To09_30_2013" id="Factid_395">P15Y</bcli:ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus>

  <bcli:ResearchLicenseLiability contextRef="PAsOn12_24_2009_InitialResearchPeriodMemberusgaapIncomeStatementLocationAxis" id="Factid_396" unitRef="USD" decimals="-3">240000</bcli:ResearchLicenseLiability>

  <bcli:ResearchLicenseLiability contextRef="PAsOn12_24_2009_ExtendedResearchPeriodMemberusgaapIncomeStatementLocationAxis" id="Factid_397" unitRef="USD" decimals="-3">380000</bcli:ResearchLicenseLiability>

  <bcli:ProceedsFromSaleOfSharesAreLessThan240Conditions contextRef="P01_01_2009To12_31_2009" id="Factid_398">Company would pay to Ramot the difference between the proceeds that Ramot has received from sales of the shares up to such date together with the September Payment (if any) that has been transferred to Ramot up to such date, and $240.</bcli:ProceedsFromSaleOfSharesAreLessThan240Conditions>

  <bcli:ResearchAndLicenseAgreementTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_399"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;NOTE 4&amp;#160;-&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;RESEARCH AND LICENSE AGREEMENT&lt;/font&gt;&lt;font style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal" dir="rtl"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; The Company has a Research and License Agreement, as amended and restated, with Ramot. The Company obtained a waiver and release from Ramot pursuant to which Ramot agreed to an amended payment schedule regarding the Company's payment obligations under the Research and License Agreement and waived all claims against the Company resulting from the Company's previous defaults and non-payment under the Research and License Agreement. The waiver and release amended and restated the original payment schedule under the original agreement providing for payments during the initial research period and additional payments for any extended research period.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; As of December 24, 2009, the Company had paid to Ramot $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;400&lt;/font&gt; but did not make payments totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;240&lt;/font&gt; for the initial research period and payments totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;380&lt;/font&gt; for the extended research period.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; On December 24, 2009, the Company and Ramot entered into a settlement agreement which amended the Research and License Agreement, as amended and restated pursuant to which, among other things, the following matters were agreed upon:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt 56.7pt"&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;a)&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; Ramot released the Company from its obligation to fund the extended research period in the total amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,140&lt;/font&gt;. Therefore, the Company reversed an amount in 2009, equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;760&lt;/font&gt;, from it research and development expenses that were previously expensed.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt 85.05pt"&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;b)&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; Past due amounts of $240 for the initial research period plus interest of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;32&lt;/font&gt; owed by the Company to Ramot was converted into &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,120,000&lt;/font&gt; shares of common stock on December 30, 2009. Ramot was required to deposit the shares with a broker and only sell the shares in the open market after &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 185&lt;/font&gt; days from the issuance date.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; unicode-bidi: embed; DIRECTION: ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;c)&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; In the event that the total proceeds generated by sales of the shares on December 31, 2010, together with the March 31, 2010 payment, were less than $240 on or prior to December 31, 2010, then on such date the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Company would pay to Ramot the difference between the proceeds that Ramot has received from sales of the shares up to such date together with the September Payment (if any) that has been transferred to Ramot up to such date, and $240.&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;51&lt;/font&gt; was recorded as research and development expenses.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt"&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="15%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; In January 2011, Ramot sold an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 167,530&lt;/font&gt; shares of Common Stock of the Company, for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;35&lt;/font&gt;, which finalized the sale of the 1,120,000 Common Stock of the Company granted to Ramot for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;235&lt;/font&gt;. In February 2011, the Company paid the remaining $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; and finalized the balance due to Ramot according to the settlement agreement between the parties dated December 24, 2009.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in"&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt; &lt;font style="TEXT-INDENT: 0in; MARGIN: 0in; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in"&gt; &lt;font style="TEXT-INDENT: 0in; MARGIN: 0in; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 9.26%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="9%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &lt;font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90.74%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"&gt; The Company is to pay Ramot royalties on Net Sales on a Licensed Product by Licensed Product and jurisdiction by jurisdiction basis as follow:&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt; &amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;a)&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; So long as the making, producing, manufacturing, using, marketing, selling, importing or exporting of such Licensed Product is covered by a Valid Claim or is covered by Orphan Drug Status in such jurisdiction &amp;#150; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;% of all Net Sales.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt 56.7pt"&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="10%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="5%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;b)&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="85%"&gt; &lt;div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; In the event the making, producing, manufacturing, using, marketing, selling, importing or exporting of such Licensed Product is not covered by a Valid Claim and not covered by Orphan Drug status in such jurisdiction &amp;#150; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt;% of all Net Sales until the expiration of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt; years from the date of the First Commercial Sale of such Licensed Product in such jurisdiction.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcli:ResearchAndLicenseAgreementTextBlock>

  <bcli:ConsultingAgreementDate contextRef="P01_01_2004To12_31_2004_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_400">2004-07-08</bcli:ConsultingAgreementDate>

  <bcli:MonthlyPaymentOfConsultingFees contextRef="P01_01_2004To12_31_2004_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_401" unitRef="USD" decimals="-3">6000</bcli:MonthlyPaymentOfConsultingFees>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P01_01_2004To12_31_2004_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_402" unitRef="shares" decimals="INF">1097215</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <bcli:CommonStockExercisePrice contextRef="P01_01_2004To12_31_2004_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_403" unitRef="USD_per_Share" decimals="2">0.01</bcli:CommonStockExercisePrice>

  <bcli:MonthlyPaymentOfConsultingFees contextRef="P01_01_2012To12_31_2012_ProfDanielOffenConsultantMemberusgaapTitleOfIndividualAxis" id="Factid_404" unitRef="USD" decimals="-3">6000</bcli:MonthlyPaymentOfConsultingFees>

  <bcli:MonthlyPaymentOfConsultingFeesCash contextRef="P01_01_2012To12_31_2012_ProfDanielOffenConsultantMemberusgaapTitleOfIndividualAxis" id="Factid_405" unitRef="USD" decimals="-3">3000</bcli:MonthlyPaymentOfConsultingFeesCash>

  <bcli:MonthlyPaymentOfConsultingFeesStock contextRef="P01_01_2012To12_31_2012_ProfDanielOffenConsultantMemberusgaapTitleOfIndividualAxis" id="Factid_406" unitRef="USD" decimals="-3">3000</bcli:MonthlyPaymentOfConsultingFeesStock>

  <bcli:SharesApprovedForServices contextRef="PAsOn12_31_2010_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_407" unitRef="shares" decimals="INF">1100000</bcli:SharesApprovedForServices>

  <bcli:StockBasedCompensationRecordedAsResearchDevelopmentExpenses contextRef="P01_01_2010To12_31_2010_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_408" unitRef="USD" decimals="-3">220000</bcli:StockBasedCompensationRecordedAsResearchDevelopmentExpenses>

  <bcli:ConsultantChargesCancelled contextRef="P01_01_2010To12_31_2010_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_409" unitRef="USD" decimals="-3">487000</bcli:ConsultantChargesCancelled>

  <bcli:AdditionalSharesApprovedForServices contextRef="PAsOn12_31_2011_ProfDanielOffenConsultantMemberusgaapTitleOfIndividualAxis" id="Factid_410" unitRef="shares" decimals="INF">400000</bcli:AdditionalSharesApprovedForServices>

  <bcli:StockBasedCompensationRecordedAsResearchDevelopmentExpenses contextRef="P01_01_2011To12_31_2011_ProfDanielOffenConsultantMemberusgaapTitleOfIndividualAxis" id="Factid_411" unitRef="USD" decimals="-3">192000</bcli:StockBasedCompensationRecordedAsResearchDevelopmentExpenses>

  <bcli:AdditionalSharesApprovedForServices contextRef="PAsOn12_31_2012_ConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_412" unitRef="shares" decimals="INF">623077</bcli:AdditionalSharesApprovedForServices>

  <bcli:StockBasedCompensationRecordedAsResearchDevelopmentExpenses contextRef="P01_01_2012To12_31_2012_ConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_413" unitRef="USD" decimals="-3">162000</bcli:StockBasedCompensationRecordedAsResearchDevelopmentExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2013To09_30_2013_ConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_414" unitRef="shares" decimals="INF">216000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedAsResearchDevelopmentExpenses contextRef="P01_01_2013To09_30_2013_ConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_415" unitRef="USD" decimals="-3">54000</bcli:StockBasedCompensationRecordedAsResearchDevelopmentExpenses>

  <bcli:WarrantsExercisableTerm contextRef="P01_01_2004To12_31_2004_EldadMelamedAndDanielOffenConsultantsMemberusgaapTitleOfIndividualAxis" id="Factid_416">P7Y</bcli:WarrantsExercisableTerm>

  <bcli:ConsultingAgreementsTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_417"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="clear:both;BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;strong&gt;NOTE 5&amp;#160;-&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 90%; BACKGROUND-COLOR: transparent" valign="top" width="90%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;strong&gt;CONSULTING AGREEMENTS&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" dir="ltr" align="left"&gt; &lt;table style="clear:both;BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 5%; BACKGROUND-COLOR: transparent" valign="top" width="5%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; A.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 85%; BACKGROUND-COLOR: transparent" valign="top" width="85%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;July 8, 2004&lt;/font&gt;, the Company entered into two consulting agreements with Prof. Eldad Melamed and Dr. Daniel Offen (together, the "Consultants"), under which the Consultants provide the Company scientific and medical consulting services in consideration for a monthly payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt; each. In addition, the Company granted each of the Consultants, a fully vested warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,097,215&lt;/font&gt; shares of Common Stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.01&lt;/font&gt; per share. The warrants issued pursuant to the agreement were issued to the Consultants effective as of November 4, 2004. Each of the warrants is exercisable for a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; seven&lt;/font&gt;-year period beginning on November 4, 2005. As of September 2010, all the above warrants had been exercised. In June 2012 an amendment was signed with Dr. Daniel Offen, according to which the company pays Daniel Offen a monthly payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;, out of which $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt; in cash and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt; by grant of Company stock.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" dir="ltr"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" dir="ltr" align="left"&gt; &lt;table style="clear:both;BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 5%; BACKGROUND-COLOR: transparent" valign="top" width="5%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;strong&gt;B&lt;/strong&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 85%; BACKGROUND-COLOR: transparent" valign="top" width="85%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On December 16, 2010, the Company approved a grant of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,100,000&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;shares of the Company's Common Stock&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;to the two Consultants,&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;for services rendered through December 31, 2010. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;220&lt;/font&gt; was recorded as research and development expense.&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;A sum of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;487&lt;/font&gt; was cancelled concurrently with the issuance of the 1,100,000 shares of Common Stock of the Company.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt 113.4pt" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" dir="ltr" align="left"&gt; &lt;table style="clear:both;BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 5%; BACKGROUND-COLOR: transparent" valign="top" width="5%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;strong&gt;C&lt;/strong&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 85%; BACKGROUND-COLOR: transparent" valign="top" width="85%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On June 27, 2011, the Company approved an additional grant of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 400,000&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;shares of the Company's Common Stock&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;to Prof. Daniel Offen,&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; for services rendered through December 31, 2009. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;192&lt;/font&gt; was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 5%; BACKGROUND-COLOR: transparent" valign="top" width="5%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 85%; BACKGROUND-COLOR: transparent" valign="top" width="85%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 5%; BACKGROUND-COLOR: transparent" valign="top" width="5%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;strong&gt;D&lt;/strong&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 85%; BACKGROUND-COLOR: transparent" valign="top" width="85%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On August 1, 2012, the Company approved an additional grant of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 623,077&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;shares of the Company's Common Stock&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;to the&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;Consultants&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;,&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;for services rendered from January 1, 2011 through June 30, 2012. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;162&lt;/font&gt; was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 5%; BACKGROUND-COLOR: transparent" valign="top" width="5%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 85%; BACKGROUND-COLOR: transparent" valign="top" width="85%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 10%; BACKGROUND-COLOR: transparent" valign="top" width="10%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 5%; BACKGROUND-COLOR: transparent" valign="top" width="5%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; E.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; BORDER-BOTTOM: #f0f0f0; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #f0f0f0; PADDING-RIGHT: 0in; WIDTH: 85%; BACKGROUND-COLOR: transparent" valign="top" width="85%"&gt; &lt;div style="clear:both;unicode-bidi: embed; DIRECTION: ltr; MARGIN: 0in 0in 0pt; TEXT-INDENT: 0in" dir="ltr" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On January 16, 2013, the Company granted the Consultants an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 216,000&lt;/font&gt; shares of Common Stock for their services from January 1, 2012 through December 31, 2012.&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;54&lt;/font&gt; was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcli:ConsultingAgreementsTextBlock>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_418"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 6&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt; -&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; STOCK CAPITAL&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0in 0in 0pt 84.45pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;A.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; The rights of Common Stock are as follows:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 84.45pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Holders of Common Stock have the right to receive notice to participate and vote in general meetings of the Company, the right to a share in the excess of assets upon liquidation of the Company and the right to receive dividends, if declared.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Common Stock is registered and publicly traded on the OTC Markets Group service of the National Association of Securities Dealers, Inc. under the symbol BCLI.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;B.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Issuance of shares, warrants and options:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 113.05pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Private placements and public offering:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; (a)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/strong&gt; &lt;font style="FONT-SIZE: 10pt"&gt;During 2004 and 2005 the Company issued, in separate transactions, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 8,861,875&lt;/font&gt;&lt;/font&gt; shares of Common Stock of the Company for total proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;308&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; (b)&lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; On February 23, 2005, the Company completed a private placement for sale of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,894,808&lt;/font&gt; units for total proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,418&lt;/font&gt;. Each unit consisted of one share of Common Stock and a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; three-year&lt;/font&gt; warrant to purchase one share of Common Stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.50&lt;/font&gt; per share. This private placement was consummated in three tranches which closed in October 2004, November 2004 and February 2005.&amp;#160;All warrants are no longer valid.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; (c)&lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; On August 11, 2005, the Company signed a private placement agreement with investors for the sale of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,250,000&lt;/font&gt; units at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.80&lt;/font&gt; per unit. Each unit consisted of one share of Common Stock and one warrant to purchase one share of Common Stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.00&lt;/font&gt; per share. The warrants were exercisable for a period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; three years&lt;/font&gt; from issuance. On September 30, 2005, the Company sold &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 312,500&lt;/font&gt; units for total net proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;225&lt;/font&gt;. On December 7, 2005, the Company sold &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 187,500&lt;/font&gt; units for total net proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;135&lt;/font&gt;.&amp;#160;All warrants are no longer valid.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; (d)&lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; In July 2007, the Company entered into an investment agreement, that was amended in August 2009, according to which for an aggregate subscription price of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; million, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 41,666,667&lt;/font&gt; shares of Common Stock and a warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,083,333&lt;/font&gt; shares of the Company's common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.20&lt;/font&gt; per share and a warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 20,166,667&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.29&lt;/font&gt; per share. The warrants may be exercised at any time and expire on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;November 5, 2013&lt;/font&gt;. In May 2012 the warrants were extended by additional 18 months, through May 5, 2015.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In January 2011, the Company and an investor signed an agreement to balance the remaining amount due to the investor, totaling $2&lt;strong&gt;2&lt;/strong&gt;, against the remaining balance of the investment and the Company issued the above shares and warrants.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In addition, the Company issued an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,250,000&lt;/font&gt; shares of Common Stock to a related party as an introduction fee for the investment. As of the balance sheet date, no warrants have been exercised.&lt;/font&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt 113.05pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;(e)&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In January 2010, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,250,000&lt;/font&gt; units to a private investor for total proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250&lt;/font&gt;. Each unit consisted of one share of Common Stock and a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; two-year&lt;/font&gt; warrant to purchase one share of Common Stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.50&lt;/font&gt; per share. All warrants are no longer valid.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; (f)&lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; In February 2010, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,000,000&lt;/font&gt; shares of Common Stock to three investors (&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,000,000&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; to each investor) and warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,000,000&lt;/font&gt; shares of Common Stock (&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,000,000&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; to each investor) with an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.50&lt;/font&gt; for aggregate proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,500&lt;/font&gt; ($&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;500&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; each).&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; (g)&lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; In February 2011, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 833,333&lt;/font&gt; shares of Common Stock, at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.30&lt;/font&gt; per share, and a warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 641,026&lt;/font&gt; shares of the Company's Common Stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.39&lt;/font&gt; per share exercisable for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;one year&lt;/font&gt; for total proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250&lt;/font&gt;. The warrants are no longer valid.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; (h)&lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; On February 23, 2011, the Company entered into an investment agreement, pursuant to which the Company agreed to sell up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 12,815,000&lt;/font&gt; shares of Common Stock, for an aggregate subscription price of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.6&lt;/font&gt; million and warrants to purchase up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 19,222,500&lt;/font&gt; shares of Common Stock as follows: warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 12,815,000&lt;/font&gt; shares of Common Stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.5&lt;/font&gt; per share for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;two years&lt;/font&gt;, and warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,407,500&lt;/font&gt; shares of Common Stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.28&lt;/font&gt; per share for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;one year&lt;/font&gt;, out of which &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 946,834&lt;/font&gt; were exercised, and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,460,666&lt;/font&gt; were cancelled.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -31.5pt; MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -2.25pt; MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In addition, the Company agreed to pay &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of the funds received for the distribution services received, out of this amount, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4&lt;/font&gt;% was be paid in stock and the remaining &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;% in cash. Accordingly, in March 2011, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 512,600&lt;/font&gt; shares of Common Stock and paid $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;231&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -31.5pt; MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; (I)&lt;/font&gt;&lt;/strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; On July 17, 2012, the Company raised $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.7&lt;/font&gt; million gross proceeds through a public offering (&amp;#8220;Public Offering&amp;#8221;) of its common stock. The Company issued a total of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 19,818,968&lt;/font&gt; common stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.00005&lt;/font&gt; par value, ($&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.29&lt;/font&gt; per share) and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 14,864,228&lt;/font&gt; warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.75&lt;/font&gt; shares of Common Stock for every share purchased in the Public Offering, at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.29&lt;/font&gt; per share. The Warrants are exercisable until the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;30 month&lt;/font&gt; anniversary of the date of issuance. After deducting closing costs and fees, the Company received net proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.9&lt;/font&gt;&amp;#160;million.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -31.5pt; MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company paid to the Placement Agency, Maxim Group LLC (the &amp;#8220;Placement Agent&amp;#8221;) a cash fee equal to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;% of the gross proceeds of the Public Offering and a corporate finance fee of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1&lt;/font&gt;% of the gross proceeds of the Public Offering.&amp;#160;In addition, the Company issued to the Placement Agent a two year warrant to purchase up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 493,966&lt;/font&gt; shares of Common Stock (equal to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt;% of the number of shares sold in the Public Offering), with an exercise price equal to&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.348&lt;/font&gt; (&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;120&lt;/font&gt;% of the Public offering price). The Warrants are exercisable until the 30 month anniversary of the date of issuance. In addition, the Company issued to Leader Underwriters (1993) Ltd, warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 232,758&lt;/font&gt; shares of Common stock, at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.29&lt;/font&gt; per share. The warrants are exercisable until the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;30 month&lt;/font&gt; anniversary of the date of issuance.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -31.5pt; MARGIN: 0in 0in 0pt 2in" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;(j)&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On August 16, 2013,&amp;#160;the Company raised $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4&lt;/font&gt; million gross proceeds through a public offering (&amp;#8220;Public Offering&amp;#8221;) of its common stock. The Company issued a total of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 23,529,411&lt;/font&gt; common stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.00005&lt;/font&gt; par value, ($&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.17&lt;/font&gt; per share) and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 17,647,058&lt;/font&gt; warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.75&lt;/font&gt; shares of Common Stock for every share purchased in the Public Offering, at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.25&lt;/font&gt; per share. The Warrants are exercisable until the 36 month anniversary of the date of issuance. The Warrants also include, subject to certain exceptions, full ratchet anti-dilution protection in the event of the issuance of any common stock, securities convertible into common stock, or certain other issuances at a price below the then-current exercise price of the Warrants, which would result in an adjustment to the exercise price of the Warrants. In the event of a sale of the Company, each holder of Warrants has the right, exercisable at its option, to require the Company to purchase such holder&amp;#8217;s Warrants at a price determined using a Black-Scholes option pricing model as described in the Warrants. After deducting closing costs and fees, the Company received net proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.3&lt;/font&gt;&amp;#160;million.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;(k)&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On February 7, 2013, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 833,334&lt;/font&gt;&amp;#160;units to a private investor for total proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250&lt;/font&gt;. Each unit consisted of one share of Common Stock and a warrant to purchase one share of Common Stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.50&lt;/font&gt; per share exercisable for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;32 months&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On November 25, 2004, the Company's stockholders approved the 2004 Global Stock Option Plan and the Israeli Appendix thereto (which applies solely to participants who are residents of Israel) and on March 28, 2005, the Company's stockholders approved the 2005 U.S. Stock Option and Incentive Plan, and the reservation of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 9,143,462&lt;/font&gt; shares of Common Stock for issuance in the aggregate under these stock plans.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Each option granted under the plans is exercisable until the earlier of ten years from the date of grant of the option or the expiration dates of the respective option plans. The 2004 and 2005 options plans will expire on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;November 25, 2014&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;March 28, 2015&lt;/font&gt;, respectively. The exercise price of the options granted under the plans may not be less than the nominal value of the shares into which such options are exercised. The options vest primarily over three years. Any options that are canceled or forfeited before expiration become available for future grants.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In June 2008, June 2011 and in June 2012, the Company's stockholders approved increases in the number of shares of common stock available for issuance under these stock option plans by &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,000,000&lt;/font&gt;, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,000,000&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 9,000,000&lt;/font&gt; shares, respectively.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;From 2005 through 2009, the Company granted its directors options to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 800,000&lt;/font&gt; (in total) shares of Common Stock of the Company at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.15&lt;/font&gt; per share. The options are fully vested and will expire after &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt; years.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 113.05pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Share-based compensation to employees and to directors:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;(a)&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160; &amp;#160;&amp;#160;&lt;/font&gt; Options to employees and directors:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 22, 2006, the Company entered into an amendment to the Company's option agreement with two of its employees. The amendment changed the exercise price of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 270,000&lt;/font&gt; options granted to them from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.75&lt;/font&gt; to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.15&lt;/font&gt; per share. The excess of the fair value resulting from the modification, in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt;, was recorded as general and administration expense over the remaining vesting period of the options.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On October 23, 2007, the Company granted to its former Chief Executive Officer an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000,000&lt;/font&gt; shares of Common Stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.87&lt;/font&gt; per share. On November 5, 2008, the Company amended the exercise price to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.15&lt;/font&gt; per share. The option is fully vested and expires after &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt; years. The total compensation related to the option is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;737&lt;/font&gt;, which was recorded as general and administrative expense. The options were all exercised for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;150&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 29, 2009, the Company granted to its former Chief Executive Officer and director an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000,000&lt;/font&gt; shares of Common Stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.067&lt;/font&gt; per share. The option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt; years. Out of which &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 483,333&lt;/font&gt; were exercised for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;32&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 516,667&lt;/font&gt; were cancelled.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The total compensation related to the option is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;68&lt;/font&gt;, which is amortized over the vesting period as general and administrative expense. In February 2011, the former CEO resigned. On July 25, 2011, the Company signed a settlement agreement with the former CEO under which &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 483,333&lt;/font&gt; shares out of the above grant became fully vested and exercisable through April 30, 2012. An additional $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;30&lt;/font&gt; was written as compensation in general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In April 2012, the former CEO exercised the option to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 483,333&lt;/font&gt; shares of Common Stock for an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;32&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 29, 2009, the Company granted to its former Chief Financial Officer an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 200,000&lt;/font&gt; shares of Common Stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.067&lt;/font&gt; per share. The option vested with respect to 1/3 of the shares subject to the option. In connection with the former Chief Financial Officer&amp;#8217;s resignation, 2/3 of the above shares were cancelled and the remaining &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 66,667&lt;/font&gt; were exercised for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On April 13, 2010, the Company, Abraham Israeli and Hadasit Medical Research Services and Development Ltd. (&amp;#8220;Hadasit&amp;#8221;) entered into an Agreement (the &amp;#8220;Agreement&amp;#8221;) pursuant to which Prof. Israeli agreed, during the term of the Agreement, to serve as (i) the Company&amp;#8217;s Clinical Trials Advisor and (ii) a member of the Company&amp;#8217;s Board of Directors.&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In consideration of the services to be provided by Prof. Israeli to the Company under the Agreement, the Company agreed to grant equity annually during the term of the Agreement for the purchase of its Common Stock, as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.85pt; MARGIN: 0in 0in 0pt 159.6pt" align="justify"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#8901;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; An option for the purchase of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 166,666&lt;/font&gt; shares of Common Stock at an exercise price equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.00005&lt;/font&gt; per share to Prof. Israeli; and&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.85pt; MARGIN: 0in 0in 0pt 159.6pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.85pt; MARGIN: 0in 0in 0pt 159.6pt" align="justify"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; A warrant for the purchase of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 33,334&lt;/font&gt; shares of Common Stock at an exercise price equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.00005&lt;/font&gt; per share to Hadasit,&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="left"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt 141.75pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Such options and warrants will vest and become exercisable in twelve (12) consecutive equal monthly amounts.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Accordingly, the Company granted to Prof. Israeli in each of April 2010, June 2011, April 2012 and April 2013, an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 166,666&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; shares of Common Stock at an exercise price equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.00005&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; per share. The aggregated compensation related to such warrants recorded as of December 31, 2012 is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;126&lt;/font&gt; was classified as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In addition, the Company granted Hadasit, in each of April 2010, June 2011, April 2012 and April 2013, a warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 33,334&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; shares of Common Stock at an exercise price equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.00005&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; per share. The aggregated compensation related to the options recorded as of December 31, 2012 is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;24&lt;/font&gt; was classified as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 16, 2010, the Company granted to two of its directors an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 400,000&lt;/font&gt; shares of Common Stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.15&lt;/font&gt; per share. The options are fully vested and are exercisable for a period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt; years. The compensation related to the option, in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;78&lt;/font&gt;, was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 16, 2010, the Company approved the grant to its three Scientific Board members &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 300,000&lt;/font&gt; shares of Common Stock of the Company. The compensation related to the option, in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;60&lt;/font&gt;, was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In January 2011, the Company granted to its former CEO, an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 450,000&lt;/font&gt; shares of Common Stock of the Company at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.20&lt;/font&gt; per share. The total compensation related to the option is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;177&lt;/font&gt;, which is amortized over the vesting period as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 27, 2011, the Company granted to three of its directors options to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 634,999&lt;/font&gt; shares of Common Stock of the Company at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.15&lt;/font&gt; per share. The total compensation related to the option was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;287&lt;/font&gt;, which is amortized over the vesting period as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On August 10, 2011, the Company granted to its CEO, an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 70,000&lt;/font&gt; shares of Common Stock of the Company at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.20&lt;/font&gt; per share. The total compensation related to the option was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;26&lt;/font&gt;, which was amortized as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On August 1, 2012, the Company granted to three of its directors options to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 460,000&lt;/font&gt; shares of Common Stock of the Company at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.15&lt;/font&gt; per share. The total compensation related to the option was $&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;105&lt;/font&gt;&lt;/strong&gt;, which is amortized over the vesting period as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On August 1, 2012, the Company granted to its former CEO, an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 70,000&lt;/font&gt; shares of Common Stock of the Company at &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.26&lt;/font&gt; per share. The total compensation expense related to the option was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16&lt;/font&gt;, which was amortized as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On January 24, 2013, the Company granted its former Chief Executive Officer an option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4,000,000&lt;/font&gt; shares of Common Stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.29&lt;/font&gt; per share. The option will vest &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 33&lt;/font&gt;% of the shares subject thereto on the first anniversary of the date of grant and the remainder shall vest over &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;36&lt;/font&gt; consecutive months. On July&amp;#160;28, 2013, the former CEO informed the Company of his resignation from his position with the Company. In connection with the former CEO&amp;#8217;s resignation on July 28, 2013, the above options were cancelled and the total compensation expense related to the option that was recorded as general and administrative expense was cancelled.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On April 19, 2013, the Company granted to three of its directors options to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 460,000&lt;/font&gt; shares of Common Stock of the Company at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.15&lt;/font&gt; per share. The total compensation expense related to the option will be recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;A summary of the Company's option activity related to options to employees and directors, and related information is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.97in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="5"&gt; &lt;div&gt;For&amp;#160;the&amp;#160;nine&amp;#160;months&amp;#160;ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="5"&gt; &lt;div&gt;September&amp;#160;30,&amp;#160;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Amount&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Outstanding at beginning of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,751,665&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.1803&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,626,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.2656&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(4,006,667)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.2898&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Outstanding at end of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,371,664&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.1721&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;96,166&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Vested and expected-to-vest at end of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,943,609&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.1764&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;67,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the fair market value of the Company&amp;#8217;s shares on September 30, 2013 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2013.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0pt 141.85pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;(b)&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160; &amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Restricted shares to directors:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;From May 2006 through April 2007, the Company issued to its directors &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 400,000&lt;/font&gt; restricted shares of Common Stock (100,000 each). The restrictions on the shares have fully lapsed. The compensation related to the stocks issued amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;198&lt;/font&gt;, which was amortized over the vesting period as general and administrative expenses. On August 27, 2008, the Company issued to its director &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 960,000&lt;/font&gt; shares of Common Stock upon a cashless exercise by a shareholder of a warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000,000&lt;/font&gt; shares of Common Stock at an exercise price of $.01 per share that was acquired by the shareholder from Ramot. The shares were allocated to the director by the shareholder.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In May and June 2010, based on a board resolution dated June 29, 2009, the Company issued to three directors, three of its Scientific Advisory Board members and two of its Advisory Board members &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 800,000&lt;/font&gt; restricted shares of Common Stock. The shares will vest in three annual and equal portions commencing with the grant date.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 16, 2010, the Company approved a grant to two of its directors &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 400,000&lt;/font&gt; (total) shares of Common Stock. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;80&lt;/font&gt; was recorded as general and administrative costs in 2010. These shares were actually granted in June 2011, and an additional related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;112&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="BACKGROUND: yellow; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 27, 2011, the Company granted to two of its directors &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 476,666&lt;/font&gt; (total) shares of Common Stock, which shares are fully vested as of March 31, 2013. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;229&lt;/font&gt; will be recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On August 22, 2011, the Company entered into an agreement with Chen Schor (the &amp;#8220;Executive Director Agreement&amp;#8221;) pursuant to which the Company granted to Mr. Schor &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 923,374&lt;/font&gt; shares of restricted Common Stock of the Company.&amp;#160;&amp;#160; The shares will vest over &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt; years - 1/3 upon each anniversary of the Grant Date.&amp;#160;In addition, the Company will pay $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt; per quarter to Mr. Schor for his services as an Executive Board Member.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In August 2011, the Company issued to three of its Scientific Advisory Board members and three of its Advisory Board members a total of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 300,000&lt;/font&gt; restricted shares of Common Stock. The shares will vest in equal monthly portions over the service period.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In November 2011, the Company issued to four of its Advisory Board members a total of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 500,000&lt;/font&gt; restricted shares of Common Stock. The shares will vest in equal monthly portions over the service period.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In addition, in November 2011, the Company issued to a former director &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt; shares of Common Stock. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;70&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 1.9in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In August 2012, the Company issued to two directors, four of its Scientific Advisory Board members and three of its Advisory Board members a total of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 885,000&lt;/font&gt; restricted shares of Common Stock. The shares will vest in 12 equal monthly portions over the service period. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;198&lt;/font&gt; will be recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 1.9in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On April 19, 2013, the Company issued to two of its directors and four of its Advisory Board members a total of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 760,000&lt;/font&gt; restricted shares of Common Stock. The shares will vest in 12 equal monthly portions until fully vested on the anniversary of grant. Related compensation expense in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;175&lt;/font&gt; will be recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;3.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Shares and warrants to investors and service providers:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 1.5in" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company accounts for shares and warrant grants issued to non-employees using the guidance of&amp;#160;ASC 505-50, "Equity-Based Payments to Non-Employees" (EITTF 96-18, "Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services"), whereby the fair value of such option and warrant grants is determined using a Black-Scholes options pricing model at the earlier of the date at which the non-employee's performance is completed or a performance commitment is reached.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 163.2pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 163.2pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a)&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Warrants to investors and service providers and investors:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"&gt; &lt;div&gt;Issuance&amp;#160;date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;issued&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Price&amp;#160;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;through&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;November-December 2004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,600,845&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,396,010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;204,835&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00005 - 0.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February-December 2005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,058,471&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;173,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,548,308&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;337,163&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.15 - 2.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;337,163&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Jun - Dec 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February-December 2006&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,686,355&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;727,696&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;478,659&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;480,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.005 &amp;#150; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;480,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Feb - May 2016&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;March 2007&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,803,300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,003,300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,800,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.15 - 0.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,800,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;May 2015 &amp;#150; Oct 2017&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2008&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.15 - 0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;May 2015 &amp;#150; Sep 2018&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;Apr-Oct 2009&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,937,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;100,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,837,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.067 &amp;#150; 0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,837,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;May 2015 &amp;#150; Oct 2019&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;January 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Feb 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Apr 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;January 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,537,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,537,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,537,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;May 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;641,026&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;641,026&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.39&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,407,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;946,834&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,460,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.28&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,815,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,815,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Apr 2021&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Apr 2022&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;July 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;493,966&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;493,966&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.348&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;493,966&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Jul 2014&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;July 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;232,758&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;232,758&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;232,758&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Jan 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;July 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,864,228&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,864,228&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,864,228&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Jan 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;Feb 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;833,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;833,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;833,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Oct 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,889&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;April 2023&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;August 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,647,058&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,647,058&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,647,058&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;August 2016&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;112,742,177&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,468,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;27,401,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;68,871,843&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;68,352,398&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.1pt; MARGIN: 0in 0in 0in 2in" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; (a)&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Warrants to investors and service providers and investors:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The fair value for the warrants to service providers was estimated on the measurement date determined using a Black-Scholes option pricing model, with the following weighted-average assumptions for the year ended December 31, 2010; weighted average volatility of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 140&lt;/font&gt;%, risk free interest rates of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2.39&lt;/font&gt;%-&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.14&lt;/font&gt;%, dividend yields of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;% and a weighted average life of the options of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5&lt;/font&gt;-&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.5&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1&lt;/font&gt;-&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9&lt;/font&gt; years. There were no grants to service providers during 2012 and 2013 using Black-Scholes calculation.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;(b)&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; Shares:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 1 and June 4, 2004, the Company issued 40,000 and 150,000 shares of Common Stock for &lt;font style=" "&gt;12 months&lt;/font&gt; of filing services and legal and due-diligence services, respectively, with respect to a private placement. Compensation expense related to filing services, totaling $26, was amortized over a 12-month period. Compensation related to legal services, totaling $105 was recorded as equity issuance cost and had no effect on the statement of operations.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On February 10, 2005, the Company signed an agreement with one of its service providers under which the Company issued to the service provider 100,000 restricted shares at a purchase price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.00005&lt;/font&gt; par value under the U.S. Stock Option and Incentive Plan of the Company. All restrictions on these shares have lapsed.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In March and in April 2005, the Company signed an agreement with four members of its Scientific Advisory Board under which the Company issued to the members of the Scientific Advisory Board &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 400,000&lt;/font&gt; restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan (100,000 each). All restrictions on these shares have lapsed.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Between the years 2004 through 2009, the Company issued to several services providers, in separate transactions, 3,045,508 shares of Common Stock in total. The total related compensation, in the amount of $758, was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On March 5, 2007, the Company issued a $150 Convertible Promissory Note to a third party. Interest on the note accrued at the rate of 8% per annum for the first year and 10% per annum after the first year. On January 27, 2010, the third party converted the entire accrued principle and interest outstanding under the note, amounting to $189, into 1,016,109 shares of Common Stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On October 29, 2007, the Company issued to a Scientific Advisory Board member 80,000 shares of the Company&amp;#8217;s Common Stock for scientific services. Compensation of $67 was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On May 20, 2008, the Company issued to its finance advisor 90,000 shares of the Company's common stock. The shares are for $35 payable to the finance advisor for introduction fee of past convertible loans. Related compensation in the amount of $36 is recorded as finance expenses.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On April 5, 2009, the Company issued to its Chief Technology Advisor &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,800,000&lt;/font&gt; shares of Common Stock. The shares are for $180 payable to the advisor. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;144&lt;/font&gt; was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On October 1, 2009, the Company issued to its service provider &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 150,000&lt;/font&gt; shares of the Company's Common Stock. The shares are for financial and investor relation services done by the provider. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;51&lt;/font&gt; is recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On October 2, 2009, the Company issued to its service provider &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,250,000&lt;/font&gt; shares of the Company's Common Stock. The shares are for investor and public relation services. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;400&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 30, 2009, the Company issued to Ramot &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,120,000&lt;/font&gt; shares of the Company's Common Stock (See Note 4).&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="BACKGROUND: yellow; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 13, 2009, the Company issued a $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;135&lt;/font&gt; Convertible Promissory Note to it legal advisor for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;217&lt;/font&gt; in legal fees accrued through October 31, 2009. Interest on the note accrued at the rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4&lt;/font&gt;%.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On January 5, 2010, the Company issued to its public relations advisor &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50,000&lt;/font&gt; shares of the Company's Common Stock for six months service. The issuance of the shares is part of the agreement with the public relations advisor that entitles it to a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; monthly&lt;/font&gt; grant of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 8,333&lt;/font&gt; shares of the Company's Common Stock. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;12&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On January 6, 2010, the Company issued to its service provider &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 60,000&lt;/font&gt; shares of the Company's Common Stock. The shares are for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt; payable to the service provider for insurance and risk management consulting and agency services for three years. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On February 19, 2010, the Company's legal advisor converted the entire accrued principal and interest amount outstanding under the note into &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 402,385&lt;/font&gt; shares of Common Stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 143pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On April 6, 2010, Prof. Melamed fully exercised his warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,097,215&lt;/font&gt; shares of the Company&amp;#8217;s Common Stock. The warrant was issued to him pursuant to the agreement with the Consultants effective as of November 4, 2004 (See Note 5a).&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In May 2010, based on a board resolution dated June 29, 2009, the Company issued to one of its public relations advisors &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100,000&lt;/font&gt; restricted shares of Common Stock. The shares will vest in three annual and equal portions commencing with the grant date.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 16, 2010, the Company granted to its service provider &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 200,000&lt;/font&gt; shares of the Company's Common Stock. The shares are for investor and public relations services. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;40&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 16, 2010, the Company granted to its two consultants &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,100,000&lt;/font&gt; shares of the Company's Common Stock (See Note 5B).&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On February 18, 2011, the Company's legal advisor converted the entire accrued principal and interest of the Convertible Promissory Note granted on September 15, 2010, totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;137&lt;/font&gt;, into &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 445,617&lt;/font&gt; shares of Common Stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 27, 2011, the Company granted to its legal advisor &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 180,000&lt;/font&gt; shares of Common Stock for 2011 legal services. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;86&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 27, 2011, the Company granted to its consultant &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 400,000&lt;/font&gt; shares of the Company's Common Stock, for services rendered through December 31, 2009.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 170.1pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;192&lt;/font&gt; was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On June 27, 2011, the Company granted to a service provider &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,870&lt;/font&gt; shares of the Company's Common Stock. Related compensation in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 31, 2011, the Company issued to Hadasit warrants to purchase up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,500,000&lt;/font&gt; restricted shares of the Company's Common Stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt; per share, exercisable for a period of 5 years.&amp;#160;&amp;#160;The warrants shall vest over the course of the trials as follows: &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 500,000&lt;/font&gt; upon enrollment of 1/3 of the patients; an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 500,000&lt;/font&gt; upon enrollment of all the patients and the final &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 500,000&lt;/font&gt; upon completion of the study.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On January 16, 2013, the Company granted an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 216,000&lt;/font&gt; shares of Common Stock of the Company to two consultants, for services rendered through December 31, 2012. Related compensation expense in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;54&lt;/font&gt; was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On February 4, 2013, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 126,111&lt;/font&gt; shares of Common Stock to an investor, according to a settlement agreement, for the correction of the conversion rate of a $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;200&lt;/font&gt; convertible loan. The convertible loan was issued in 2006 and converted in 2010.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On March 11, 2013, the Company granted to its legal advisor &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 193,696&lt;/font&gt; shares of Common Stock for 2013 legal services. As of June 30, 2013, related compensation expense in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;22&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 163.2pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On March 11, 2013, the Company granted to two of its service providers an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 400,000&lt;/font&gt; shares of the Company's Common Stock. The shares are public relations services. As of September 30, 2013, related compensation expense in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;92&lt;/font&gt; was recorded as general and administrative expense.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The total stock-based compensation expense, related to shares, options and warrants granted to employees, directors and service providers, was comprised, at each period, as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.79in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Period&amp;#160;from&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;September&amp;#160;22,&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2000&amp;#160;(inception&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;Nine&amp;#160;months&amp;#160;ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;Three&amp;#160;months&amp;#160;ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;date)&amp;#160;through&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;Unaudited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;Unaudited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Unaudited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;101&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,867&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;521&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;441&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(71)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;145&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11,179&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;Financial expenses, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;248&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;Total stock-based&lt;br/&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160;compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;622&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;485&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(64)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;164&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29,294&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis" id="Factid_419" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis" id="Factid_420" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis" id="Factid_421" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis" id="Factid_422" unitRef="USD_per_Share" decimals="1">2.5</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis" id="Factid_423" unitRef="USD_per_Share" decimals="3">0.005</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis" id="Factid_424" unitRef="USD_per_Share" decimals="1">1.5</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis" id="Factid_425" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis" id="Factid_426" unitRef="USD_per_Share" decimals="2">0.47</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis" id="Factid_427" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis" id="Factid_428" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MinimumMemberusgaapRangeAxis" id="Factid_429" unitRef="USD_per_Share" decimals="3">0.067</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis_MaximumMemberusgaapRangeAxis" id="Factid_430" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2004To12_31_2004_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_431" unitRef="shares" decimals="INF">8861875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:UnitSoldComprisedOfOneShareAndOneWarrant contextRef="P02_01_2005To02_28_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_432" unitRef="shares" decimals="INF">1894808</bcli:UnitSoldComprisedOfOneShareAndOneWarrant>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P02_01_2005To02_28_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_433" unitRef="USD" decimals="-3">1418000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P02_01_2005To02_28_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_434" unitRef="USD_per_Share" decimals="2">2.50</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2005To12_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_435" unitRef="shares" decimals="INF">8861875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P01_01_2005To12_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_436" unitRef="USD" decimals="-3">308000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <bcli:UnitSoldComprisedOfOneShareAndOneWarrant contextRef="P08_01_2005To08_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_437" unitRef="shares" decimals="INF">1250000</bcli:UnitSoldComprisedOfOneShareAndOneWarrant>

  <bcli:PricePerUnit contextRef="P08_01_2005To08_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_438" unitRef="USD_per_Share" decimals="2">0.80</bcli:PricePerUnit>

  <invest:InvestmentWarrantsExercisePrice contextRef="P08_01_2005To08_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_439" unitRef="USD_per_Share" decimals="2">1.00</invest:InvestmentWarrantsExercisePrice>

  <bcli:WarrantExpiryTerm contextRef="P02_01_2005To02_28_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_440">three-year</bcli:WarrantExpiryTerm>

  <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm contextRef="P08_01_2005To08_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_441">three years</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm>

  <bcli:UnitsSold contextRef="P09_01_2005To09_30_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_442" unitRef="shares" decimals="INF">312500</bcli:UnitsSold>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P09_01_2005To09_30_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_443" unitRef="USD" decimals="-3">225000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <bcli:UnitsSold contextRef="P12_01_2005To12_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_444" unitRef="shares" decimals="INF">187500</bcli:UnitsSold>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P12_01_2005To12_31_2005_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_445" unitRef="USD" decimals="-3">135000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:CommonStockSharesSubscriptions contextRef="PAsOn07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_446" unitRef="USD" decimals="-6">5000000</us-gaap:CommonStockSharesSubscriptions>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_447" unitRef="shares" decimals="INF">41666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis" id="Factid_448" unitRef="shares" decimals="INF">10083333</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis" id="Factid_449" unitRef="USD_per_Share" decimals="2">0.20</invest:InvestmentWarrantsExercisePrice>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedTwoMemberusgaapStatementEquityComponentsAxis" id="Factid_450" unitRef="shares" decimals="INF">20166667</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedTwoMemberusgaapStatementEquityComponentsAxis" id="Factid_451" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentWarrantsExercisePrice>

  <bcli:StockWarrantExpireDate contextRef="P07_01_2007To07_31_2007_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_452">2013-11-05</bcli:StockWarrantExpireDate>

  <bcli:AmountDueToInvestors contextRef="PAsOn01_31_2011" id="Factid_453" unitRef="USD" decimals="-3">22000</bcli:AmountDueToInvestors>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2011To12_31_2011_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_454" unitRef="shares" decimals="INF">1250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <invest:InvestmentWarrantsExercisePrice contextRef="P02_01_2010To02_28_2010" id="Factid_455" unitRef="USD_per_Share" decimals="2">0.50</invest:InvestmentWarrantsExercisePrice>

  <bcli:UnitSoldComprisedOfOneShareAndOneWarrant contextRef="P01_01_2010To01_31_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_456" unitRef="shares" decimals="INF">1250000</bcli:UnitSoldComprisedOfOneShareAndOneWarrant>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P01_01_2010To01_31_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_457" unitRef="USD" decimals="-3">250000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <bcli:WarrantExpiryTerm contextRef="P01_01_2010To01_31_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_458">two-year</bcli:WarrantExpiryTerm>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2010To01_31_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_459" unitRef="USD_per_Share" decimals="2">0.50</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2010To02_28_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_460" unitRef="shares" decimals="INF">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2010To02_28_2010_InvestorOneMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_461" unitRef="shares" decimals="INF">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2010To02_28_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_462" unitRef="shares" decimals="INF">3000000</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2010To02_28_2010_InvestorOneMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_463" unitRef="shares" decimals="INF">1000000</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P02_01_2010To02_28_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_464" unitRef="USD" decimals="-3">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P02_01_2010To02_28_2010_InvestorOneMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_465" unitRef="USD" decimals="-3">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2010To02_28_2010_InvestorTwoMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_466" unitRef="shares" decimals="INF">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2010To02_28_2010_InvestorThreeMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_467" unitRef="shares" decimals="INF">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2010To02_28_2010_InvestorTwoMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_468" unitRef="shares" decimals="INF">1000000</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2010To02_28_2010_InvestorThreeMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_469" unitRef="shares" decimals="INF">1000000</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P02_01_2010To02_28_2010_InvestorTwoMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_470" unitRef="USD" decimals="-3">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P02_01_2010To02_28_2010_InvestorThreeMemberusgaapTitleOfIndividualAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_471" unitRef="USD" decimals="-3">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2011To02_28_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_472" unitRef="shares" decimals="INF">833333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:CommonStockPurchasePrice contextRef="P02_01_2011To02_28_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_473" unitRef="USD_per_Share" decimals="2">0.30</bcli:CommonStockPurchasePrice>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2011To02_28_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_474" unitRef="shares" decimals="INF">641026</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P02_01_2011To02_28_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_475" unitRef="USD_per_Share" decimals="2">0.39</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P02_01_2011To02_28_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_476" unitRef="USD" decimals="-3">250000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <bcli:WarrantExpiryTerm contextRef="P02_01_2011To02_28_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_477">one year</bcli:WarrantExpiryTerm>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_478" unitRef="shares" decimals="INF">12815000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:CommonStockSharesSubscriptions contextRef="PAsOn02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_479" unitRef="USD" decimals="-5">3600000</us-gaap:CommonStockSharesSubscriptions>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_480" unitRef="shares" decimals="INF">19222500</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis" id="Factid_481" unitRef="shares" decimals="INF">12815000</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis" id="Factid_482" unitRef="USD_per_Share" decimals="1">0.5</invest:InvestmentWarrantsExercisePrice>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedTwoMemberusgaapStatementEquityComponentsAxis" id="Factid_483" unitRef="shares" decimals="INF">6407500</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedTwoMemberusgaapStatementEquityComponentsAxis" id="Factid_484" unitRef="USD_per_Share" decimals="2">0.28</invest:InvestmentWarrantsExercisePrice>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_485" unitRef="shares" decimals="INF">946834</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_486" unitRef="shares" decimals="INF">5460666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <bcli:WarrantExpiryTerm contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis" id="Factid_487">two years</bcli:WarrantExpiryTerm>

  <bcli:WarrantExpiryTerm contextRef="P02_01_2011To02_28_2011_InvestmentAgreementMemberinvestInvestmentAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_WarrantIssuedTwoMemberusgaapStatementEquityComponentsAxis" id="Factid_488">one year</bcli:WarrantExpiryTerm>

  <bcli:DistributionServicesPercentage contextRef="P02_01_2011To02_28_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_489" unitRef="pure" decimals="1">0.1</bcli:DistributionServicesPercentage>

  <bcli:DistributionServicesPercentage contextRef="P02_01_2011To02_28_2011_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_490" unitRef="pure" decimals="2">0.04</bcli:DistributionServicesPercentage>

  <bcli:DistributionServicesPercentage contextRef="P02_01_2011To02_28_2011_CashMemberusgaapCashAndCashEquivalentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_491" unitRef="pure" decimals="2">0.06</bcli:DistributionServicesPercentage>

  <bcli:DistributionServicesShares contextRef="P03_01_2011To03_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_492" unitRef="shares" decimals="INF">512600</bcli:DistributionServicesShares>

  <bcli:DistributionServicesValue contextRef="P03_01_2011To03_31_2011_CashMemberusgaapCashAndCashEquivalentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_493" unitRef="USD" decimals="-3">231000</bcli:DistributionServicesValue>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_494" unitRef="USD" decimals="-5">5700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_495" unitRef="shares" decimals="INF">19818968</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_496" unitRef="USD_per_Share" decimals="5">0.00005</us-gaap:CommonStockParOrStatedValuePerShare>

  <bcli:CommonStockPurchasePrice contextRef="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_497" unitRef="USD_per_Share" decimals="2">0.29</bcli:CommonStockPurchasePrice>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_498" unitRef="shares" decimals="INF">14864228</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <bcli:WarrantsToPurchaseCommonStockSharesRatio contextRef="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_499" unitRef="shares" decimals="INF">0.75</bcli:WarrantsToPurchaseCommonStockSharesRatio>

  <invest:InvestmentWarrantsExercisePrice contextRef="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_500" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_501" unitRef="USD" decimals="-5">4900000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm contextRef="P07_01_2012To07_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_502">30 month</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm>

  <bcli:PercentageOfCashFeeOnGrossProceedsOfOffering contextRef="P07_01_2012To07_31_2012_PlacementAgentMemberusgaapProductOrServiceAxis" id="Factid_503" unitRef="pure" decimals="2">0.06</bcli:PercentageOfCashFeeOnGrossProceedsOfOffering>

  <bcli:PercentageOfCorporateFinanceFeeOnGrossProceedsOfOffering contextRef="P07_01_2012To07_31_2012_PlacementAgentMemberusgaapProductOrServiceAxis" id="Factid_504" unitRef="pure" decimals="2">0.01</bcli:PercentageOfCorporateFinanceFeeOnGrossProceedsOfOffering>

  <bcli:WarrantsIssuedToPlacementAgentForPurchaseOfCommonStock contextRef="P07_01_2012To07_31_2012_PlacementAgentMemberusgaapProductOrServiceAxis" id="Factid_505" unitRef="shares" decimals="INF">493966</bcli:WarrantsIssuedToPlacementAgentForPurchaseOfCommonStock>

  <bcli:PercentageOfWarrantsIssuedOutOfSharesIssuedInPublicOffering contextRef="P07_01_2012To07_31_2012_PlacementAgentMemberusgaapProductOrServiceAxis" id="Factid_506" unitRef="pure" decimals="2">0.03</bcli:PercentageOfWarrantsIssuedOutOfSharesIssuedInPublicOffering>

  <invest:InvestmentWarrantsExercisePrice contextRef="P07_01_2012To07_31_2012_PlacementAgentMemberusgaapProductOrServiceAxis" id="Factid_507" unitRef="USD_per_Share" decimals="3">0.348</invest:InvestmentWarrantsExercisePrice>

  <bcli:PremiumOnWarrantExercisePriceComparedToIssuancePrice contextRef="P07_01_2012To07_31_2012_PlacementAgentMemberusgaapProductOrServiceAxis" id="Factid_508" unitRef="pure" decimals="1">1.2</bcli:PremiumOnWarrantExercisePriceComparedToIssuancePrice>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P07_01_2012To07_17_2012_LeaderUnderwriters1993LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_509" unitRef="shares" decimals="INF">232758</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P07_01_2012To07_17_2012_LeaderUnderwriters1993LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_510" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm contextRef="P07_01_2012To07_17_2012_LeaderUnderwriters1993LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_511">30 month</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm>

  <bcli:UnitSoldComprisedOfOneShareAndOneWarrant contextRef="P02_01_2013To02_28_2013_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_512" unitRef="shares" decimals="INF">833334</bcli:UnitSoldComprisedOfOneShareAndOneWarrant>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P02_01_2013To02_28_2013_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_513" unitRef="USD" decimals="-3">250000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P02_01_2013To02_28_2013_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_514" unitRef="USD_per_Share" decimals="2">0.50</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm contextRef="P02_01_2013To02_28_2013_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_515">32 months</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm>

  <bcli:SharesReservedForIssuanceUnderStockOptionPlan contextRef="P01_01_2004To12_31_2004_GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005MemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_516" unitRef="shares" decimals="INF">9143462</bcli:SharesReservedForIssuanceUnderStockOptionPlan>

  <bcli:StockOptionExpireDate contextRef="P01_01_2004To12_31_2004_GlobalShareOptionPlan2004MemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_517">2014-11-25</bcli:StockOptionExpireDate>

  <bcli:StockOptionExpireDate contextRef="P01_01_2004To12_31_2004_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_518">2015-03-28</bcli:StockOptionExpireDate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="P01_01_2008To12_31_2008_GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005MemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_519" unitRef="shares" decimals="INF">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="P01_01_2011To12_31_2011_GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005MemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_520" unitRef="shares" decimals="INF">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="P01_01_2012To12_31_2012_GlobalShareOptionPlan2004AndUSStockOptionAndIncentivePlan2005MemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_521" unitRef="shares" decimals="INF">9000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2005To12_31_2009_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_522" unitRef="shares" decimals="INF">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <invest:InvestmentOptionsExercisePrice contextRef="P01_01_2005To12_31_2009_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_523" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentOptionsExercisePrice>

  <bcli:StockOptionExpirationTerm contextRef="P01_01_2005To12_31_2009_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_524">P10Y</bcli:StockOptionExpirationTerm>

  <bcli:NumberOfOptionsExercisePriceAmended contextRef="P06_01_2006To06_30_2006_EmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_525" unitRef="shares" decimals="INF">270000</bcli:NumberOfOptionsExercisePriceAmended>

  <invest:InvestmentOptionsExercisePrice contextRef="P06_01_2006To06_30_2006_EmployeeMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis" id="Factid_526" unitRef="USD_per_Share" decimals="2">0.75</invest:InvestmentOptionsExercisePrice>

  <invest:InvestmentOptionsExercisePrice contextRef="P06_01_2006To06_30_2006_EmployeeMemberusgaapTitleOfIndividualAxis_MinimumMemberusgaapRangeAxis" id="Factid_527" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentOptionsExercisePrice>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P06_01_2006To06_30_2006_EmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_528" unitRef="USD" decimals="-3">2000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P10_01_2007To10_31_2007_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_529" unitRef="shares" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <invest:InvestmentOptionsExercisePrice contextRef="P10_01_2007To10_31_2007_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_530" unitRef="USD_per_Share" decimals="2">0.87</invest:InvestmentOptionsExercisePrice>

  <invest:InvestmentOptionsExercisePrice contextRef="P11_01_2008To11_30_2008_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_531" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentOptionsExercisePrice>

  <bcli:StockOptionExpirationTerm contextRef="P10_01_2007To10_31_2007_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_532">P10Y</bcli:StockOptionExpirationTerm>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P10_01_2007To10_31_2007_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_533" unitRef="USD" decimals="-3">737000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P10_01_2007To10_31_2007_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_534" unitRef="USD" decimals="-3">150000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P06_01_2009To06_30_2009_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_535" unitRef="shares" decimals="INF">1000000</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P06_01_2009To06_30_2009_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_536" unitRef="USD_per_Share" decimals="3">0.067</invest:InvestmentOptionsExercisePrice>

  <bcli:StockOptionExpirationTerm contextRef="P06_01_2009To06_30_2009_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_537">P10Y</bcli:StockOptionExpirationTerm>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P06_01_2009To06_30_2009_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_538" unitRef="shares" decimals="INF">483333</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P06_01_2009To06_30_2009_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_539" unitRef="USD" decimals="-3">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P06_01_2009To06_30_2009_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_540" unitRef="shares" decimals="INF">516667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P06_01_2009To06_30_2009_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_541" unitRef="USD" decimals="-3">68000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="PAsOn07_25_2011_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_542" unitRef="shares" decimals="INF">483333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P07_01_2011To07_31_2011_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_543" unitRef="USD" decimals="-3">30000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P04_01_2012To04_30_2012_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_544" unitRef="shares" decimals="INF">483333</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <invest:InvestmentOptionsExercisePrice contextRef="P04_01_2012To04_30_2012_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_545" unitRef="USD_per_Share" decimals="0">32</invest:InvestmentOptionsExercisePrice>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P06_01_2009To06_30_2009_FormerChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_546" unitRef="shares" decimals="INF">200000</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P06_01_2009To06_30_2009_FormerChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_547" unitRef="USD_per_Share" decimals="3">0.067</invest:InvestmentOptionsExercisePrice>

  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="P06_01_2009To06_30_2009_FormerChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_548" unitRef="shares" decimals="INF">66667</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P06_01_2009To06_30_2009_FormerChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_549" unitRef="USD" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P04_01_2010To04_30_2010_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_550" unitRef="shares" decimals="INF">166666</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P04_01_2010To04_30_2010_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_551" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentOptionsExercisePrice>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P04_01_2010To04_30_2010_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_552" unitRef="shares" decimals="INF">33334</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P04_01_2010To04_30_2010_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_553" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentWarrantsExercisePrice>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P06_01_2011To06_30_2011_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_554" unitRef="shares" decimals="INF">166666</bcli:CommonStockPurchasedFromOptionGranted>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P04_01_2012To04_30_2012_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_555" unitRef="shares" decimals="INF">166666</bcli:CommonStockPurchasedFromOptionGranted>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P04_01_2013To04_30_2013_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_556" unitRef="shares" decimals="INF">166666</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P06_01_2011To06_30_2011_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_557" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentOptionsExercisePrice>

  <invest:InvestmentOptionsExercisePrice contextRef="P04_01_2012To04_30_2012_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_558" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentOptionsExercisePrice>

  <invest:InvestmentOptionsExercisePrice contextRef="P04_01_2013To04_30_2013_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_559" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentOptionsExercisePrice>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P06_01_2011To06_30_2011_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_560" unitRef="shares" decimals="INF">33334</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P04_01_2012To04_30_2012_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_561" unitRef="shares" decimals="INF">33334</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P04_01_2013To04_30_2013_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_562" unitRef="shares" decimals="INF">33334</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P06_01_2011To06_30_2011_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_563" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P04_01_2012To04_30_2012_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_564" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P04_01_2013To04_30_2013_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_565" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentWarrantsExercisePrice>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P01_01_2012To12_31_2012_MrIsraeliMemberusgaapTitleOfIndividualAxis" id="Factid_566" unitRef="USD" decimals="-3">126000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses contextRef="P01_01_2012To12_31_2012_HadasitMemberusgaapTitleOfIndividualAxis" id="Factid_567" unitRef="USD" decimals="-3">24000</bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P12_01_2010To12_31_2010_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_568" unitRef="shares" decimals="INF">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <invest:InvestmentOptionsExercisePrice contextRef="P12_01_2010To12_31_2010_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_569" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentOptionsExercisePrice>

  <bcli:StockOptionExpirationTerm contextRef="P12_01_2010To12_31_2010_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_570">P10Y</bcli:StockOptionExpirationTerm>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P12_01_2010To12_31_2010_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_571" unitRef="USD" decimals="-3">78000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P12_01_2010To12_31_2010_ScientificBoardMemberusgaapTitleOfIndividualAxis" id="Factid_572" unitRef="shares" decimals="INF">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses contextRef="P12_01_2010To12_31_2010_ScientificBoardMemberusgaapTitleOfIndividualAxis" id="Factid_573" unitRef="USD" decimals="-3">60000</bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P01_01_2011To01_31_2011_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_574" unitRef="shares" decimals="INF">450000</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P01_01_2011To01_31_2011_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_575" unitRef="USD_per_Share" decimals="2">0.20</invest:InvestmentOptionsExercisePrice>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P01_01_2011To01_31_2011_FormerChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_576" unitRef="USD" decimals="-3">177000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P06_01_2011To06_30_2011_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_577" unitRef="shares" decimals="INF">634999</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P06_01_2011To06_30_2011_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_578" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentOptionsExercisePrice>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P06_01_2011To06_30_2011_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_579" unitRef="USD" decimals="-3">287000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P08_01_2011To08_31_2011_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_580" unitRef="shares" decimals="INF">70000</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P08_01_2011To08_31_2011_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_581" unitRef="USD_per_Share" decimals="2">0.20</invest:InvestmentOptionsExercisePrice>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P08_01_2012To08_31_2012_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_582" unitRef="shares" decimals="INF">460000</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P08_01_2012To08_31_2012_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_583" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentOptionsExercisePrice>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P08_01_2012To08_31_2012_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_584" unitRef="shares" decimals="INF">70000</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P08_01_2012To08_31_2012_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_585" unitRef="USD_per_Share" decimals="2">0.26</invest:InvestmentOptionsExercisePrice>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P01_01_2013To09_30_2013_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_586" unitRef="shares" decimals="INF">4000000</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P01_01_2013To09_30_2013_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_587" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentOptionsExercisePrice>

  <bcli:StockOptionsVestedPercentage contextRef="P01_01_2013To09_30_2013_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_588" unitRef="pure" decimals="2">0.33</bcli:StockOptionsVestedPercentage>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod contextRef="P01_01_2013To09_30_2013_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_589">P36M</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod>

  <bcli:CommonStockPurchasedFromOptionGranted contextRef="P04_01_2013To04_19_2013_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_590" unitRef="shares" decimals="INF">460000</bcli:CommonStockPurchasedFromOptionGranted>

  <invest:InvestmentOptionsExercisePrice contextRef="P04_01_2013To04_19_2013_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_591" unitRef="USD_per_Share" decimals="2">0.15</invest:InvestmentOptionsExercisePrice>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P05_01_2006To04_30_2007_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_592" unitRef="shares" decimals="INF">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P05_01_2006To04_30_2007_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_593" unitRef="USD" decimals="-3">198000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2008To08_31_2008_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_594" unitRef="shares" decimals="INF">960000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:CommonStockPurchasedFromIssuanceOfWarrants contextRef="P08_01_2008To08_31_2008_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_595" unitRef="shares" decimals="INF">1000000</bcli:CommonStockPurchasedFromIssuanceOfWarrants>

  <invest:InvestmentWarrantsExercisePrice contextRef="P08_01_2008To08_31_2008_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_596" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P12_01_2010To12_31_2010_DirectorOneMemberusgaapTitleOfIndividualAxis" id="Factid_597" unitRef="shares" decimals="INF">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P05_01_2010To06_30_2010_ManagementMemberusgaapTitleOfIndividualAxis" id="Factid_598" unitRef="shares" decimals="INF">800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P12_01_2010To12_31_2010_DirectorOneMemberusgaapTitleOfIndividualAxis" id="Factid_599" unitRef="USD" decimals="-3">80000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P06_01_2011To06_30_2011_DirectorOneMemberusgaapTitleOfIndividualAxis" id="Factid_600" unitRef="USD" decimals="-3">112000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P06_01_2011To06_30_2011_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_601" unitRef="shares" decimals="INF">476666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P06_01_2011To06_30_2011_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_602" unitRef="USD" decimals="-3">229000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2011To08_31_2011_MrSchorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_603" unitRef="shares" decimals="INF">923374</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P08_01_2011To08_31_2011_MrSchorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_604">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P08_01_2011To08_31_2011_MrSchorMemberusgaapTitleOfIndividualAxis" id="Factid_605" unitRef="USD" decimals="-3">15000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2011To08_31_2011_RestrictedStockMemberusgaapAwardTypeAxis_ScientificBoardMemberusgaapTitleOfIndividualAxis" id="Factid_606" unitRef="shares" decimals="INF">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P11_01_2011To11_30_2011_BoardMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_607" unitRef="shares" decimals="INF">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P11_01_2011To11_30_2011_FormerDirectorMemberusgaapTitleOfIndividualAxis" id="Factid_608" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P11_01_2011To11_30_2011_FormerDirectorMemberusgaapTitleOfIndividualAxis" id="Factid_609" unitRef="USD" decimals="-3">70000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="P08_01_2012To08_31_2012_ManagementMemberusgaapTitleOfIndividualAxis" id="Factid_610" unitRef="shares" decimals="INF">885000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>

  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="P04_01_2013To04_19_2013_ManagementMemberusgaapTitleOfIndividualAxis" id="Factid_611" unitRef="shares" decimals="INF">760000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>

  <bcli:StockBasedCompensationWillBeRecordedInGeneralAndAdministrativeExpenses contextRef="P04_01_2013To04_19_2013_ManagementMemberusgaapTitleOfIndividualAxis" id="Factid_612" unitRef="USD" decimals="-3">175000</bcli:StockBasedCompensationWillBeRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="P01_01_2010To12_31_2010_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_613" unitRef="pure" decimals="1">1.4</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2010To12_31_2010_MinimumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_614" unitRef="pure" decimals="4">0.0239</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2010To12_31_2010_MaximumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_615" unitRef="pure" decimals="4">0.0314</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2010To12_31_2010_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_616" unitRef="pure" decimals="0">0</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2010To12_31_2010_MinimumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_617">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2010To12_31_2010_MaximumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_618">P5Y6M</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2010To12_31_2010_MinimumMemberusgaapRangeAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis" id="Factid_619">P1Y</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2010To12_31_2010_MaximumMemberusgaapRangeAxis_WarrantIssuedOneMemberusgaapStatementEquityComponentsAxis" id="Factid_620">P9Y</us-gaap:FairValueAssumptionsExpectedTerm>

  <bcli:CompensationExpensesAmortizationPeriod contextRef="P06_01_2004To06_30_2004_FilingServiceMemberusgaapProductOrServiceAxis" id="Factid_621">12 months</bcli:CompensationExpensesAmortizationPeriod>

  <bcli:RestrictedSharesPrice contextRef="P02_01_2005To02_28_2005_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_622" unitRef="USD_per_Share" decimals="5">0.00005</bcli:RestrictedSharesPrice>

  <bcli:RestrictedSharesPrice contextRef="P03_01_2005To04_30_2005_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_623" unitRef="USD_per_Share" decimals="5">0.00005</bcli:RestrictedSharesPrice>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P06_01_2004To06_30_2004_FilingServiceMemberusgaapProductOrServiceAxis_MinimumMemberusgaapRangeAxis" id="Factid_624" unitRef="shares" decimals="INF">40000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P06_01_2004To06_30_2004_FilingServiceMemberusgaapProductOrServiceAxis_MaximumMemberusgaapRangeAxis" id="Factid_625" unitRef="shares" decimals="INF">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:CompensationExpensesFilingServices contextRef="P06_01_2004To06_30_2004_FilingServiceMemberusgaapProductOrServiceAxis" id="Factid_626" unitRef="USD" decimals="-3">26000</bcli:CompensationExpensesFilingServices>

  <bcli:StockBasedCompensationToLegalAdvisor contextRef="P06_01_2004To06_30_2004_FilingServiceMemberusgaapProductOrServiceAxis" id="Factid_627" unitRef="USD" decimals="-3">105000</bcli:StockBasedCompensationToLegalAdvisor>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2005To02_28_2005_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_628" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2005To04_30_2005_ScientificAdvisoryBoardOneMemberusgaapProductOrServiceAxis_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_629" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2005To04_30_2005_ScientificAdvisoryBoardTwoMemberusgaapProductOrServiceAxis_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_630" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2005To04_30_2005_ScientificAdvisoryBoardThreeMemberusgaapProductOrServiceAxis_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_631" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2005To04_30_2005_ScientificAdvisoryBoardFourMemberusgaapProductOrServiceAxis_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_632" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2005To12_31_2009_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_633" unitRef="shares" decimals="INF">3045508</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P01_01_2005To12_31_2009_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_634" unitRef="USD" decimals="-3">758000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:ConvertibleNotesPayable contextRef="PAsOn03_05_2007_ConvertiblePromissoryNoteToThirdPartyMemberusgaapProductOrServiceAxis" id="Factid_635" unitRef="USD" decimals="-3">150000</us-gaap:ConvertibleNotesPayable>

  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="PAsOn03_05_2007_ConvertiblePromissoryNoteToThirdPartyMemberusgaapProductOrServiceAxis" id="Factid_636" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>

  <bcli:DebtInstrumentInterestRateEffectivePercentageInYearOne contextRef="PAsOn03_05_2007_ConvertiblePromissoryNoteToThirdPartyMemberusgaapProductOrServiceAxis" id="Factid_637" unitRef="pure" decimals="1">0.1</bcli:DebtInstrumentInterestRateEffectivePercentageInYearOne>

  <bcli:ConvertibleLoansIntroductionFee contextRef="P05_01_2008To05_20_2008_FinancialAdvisorMemberusgaapProductOrServiceAxis" id="Factid_638" unitRef="USD" decimals="-3">35000</bcli:ConvertibleLoansIntroductionFee>

  <bcli:DebtInstrumentPrincipleWithInterest contextRef="PAsOn01_27_2010_ConvertiblePromissoryNoteToThirdPartyMemberusgaapProductOrServiceAxis" id="Factid_639" unitRef="USD" decimals="-3">189000</bcli:DebtInstrumentPrincipleWithInterest>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2010To01_27_2010_ConvertiblePromissoryNoteToThirdPartyMemberusgaapProductOrServiceAxis" id="Factid_640" unitRef="shares" decimals="INF">1016109</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P10_01_2007To10_31_2007_ScientificAdvisoryBoardMemberusgaapProductOrServiceAxis" id="Factid_641" unitRef="shares" decimals="INF">80000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses contextRef="P10_01_2007To10_31_2007_ScientificAdvisoryBoardMemberusgaapProductOrServiceAxis" id="Factid_642" unitRef="USD" decimals="-3">67000</bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P05_01_2008To05_20_2008_FinancialAdvisorMemberusgaapProductOrServiceAxis" id="Factid_643" unitRef="shares" decimals="INF">90000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:InterestAndDebtExpense contextRef="P05_01_2008To05_20_2008_FinancialAdvisorMemberusgaapProductOrServiceAxis" id="Factid_644" unitRef="USD" decimals="-3">36000</us-gaap:InterestAndDebtExpense>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2009To12_31_2009" id="Factid_645" unitRef="shares" decimals="INF">1120000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P04_01_2009To04_30_2009_ChiefTechnologyAdvisorMemberusgaapProductOrServiceAxis" id="Factid_646" unitRef="shares" decimals="INF">1800000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses contextRef="P04_01_2009To04_30_2009_ChiefTechnologyAdvisorMemberusgaapProductOrServiceAxis" id="Factid_647" unitRef="USD" decimals="-3">144000</bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P10_01_2009To10_31_2009_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_648" unitRef="shares" decimals="INF">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P10_01_2009To10_31_2009_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_649" unitRef="USD" decimals="-3">51000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P10_01_2009To10_31_2009_ServiceProviderOneMemberusgaapProductOrServiceAxis" id="Factid_650" unitRef="shares" decimals="INF">1250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P10_01_2009To10_31_2009_ServiceProviderOneMemberusgaapProductOrServiceAxis" id="Factid_651" unitRef="USD" decimals="-3">400000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:ConvertibleNotesPayable contextRef="PAsOn12_13_2009_ConvertiblePromissoryNoteToLegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_652" unitRef="USD" decimals="-3">135000</us-gaap:ConvertibleNotesPayable>

  <bcli:LegalFeesPayable contextRef="PAsOn12_13_2009_ConvertiblePromissoryNoteToLegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_653" unitRef="USD" decimals="-3">217000</bcli:LegalFeesPayable>

  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="PAsOn12_13_2009_ConvertiblePromissoryNoteToLegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_654" unitRef="pure" decimals="2">0.04</us-gaap:DebtInstrumentInterestRateEffectivePercentage>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2010To01_31_2010_PublicRelationsAdvisorMemberusgaapProductOrServiceAxis" id="Factid_655" unitRef="shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:CommonStockPeriodicIssuance contextRef="P01_01_2010To01_31_2010_PublicRelationsAdvisorMemberusgaapProductOrServiceAxis" id="Factid_656" unitRef="shares" decimals="INF">8333</bcli:CommonStockPeriodicIssuance>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2010To01_31_2010_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_657" unitRef="shares" decimals="INF">60000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2010To01_31_2010_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_658" unitRef="USD" decimals="-3">15000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P01_01_2010To01_31_2010_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_659" unitRef="USD" decimals="-3">16000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P01_01_2010To01_31_2010_PublicRelationsAdvisorMemberusgaapProductOrServiceAxis" id="Factid_660" unitRef="USD" decimals="-3">12000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P02_01_2010To02_28_2010_LegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_661" unitRef="shares" decimals="INF">402385</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <bcli:CommonStockPurchasedFromIssuanceOfWarrants contextRef="P04_01_2010To04_30_2010_ProfMelamedMemberusgaapTitleOfIndividualAxis" id="Factid_662" unitRef="shares" decimals="INF">1097215</bcli:CommonStockPurchasedFromIssuanceOfWarrants>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P05_01_2010To05_31_2010_PublicRelationsAdvisorMemberusgaapProductOrServiceAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_663" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P12_01_2010To12_31_2010_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_664" unitRef="shares" decimals="INF">200000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P12_01_2010To12_31_2010_ConsultantsMemberusgaapProductOrServiceAxis" id="Factid_665" unitRef="shares" decimals="INF">1100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P02_01_2011To02_28_2011_LegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_666" unitRef="USD" decimals="-3">137000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P02_01_2011To02_28_2011_LegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_667" unitRef="shares" decimals="INF">445617</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P06_01_2011To06_30_2011_LegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_668" unitRef="shares" decimals="INF">180000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P06_01_2011To06_30_2011_LegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_669" unitRef="USD" decimals="-3">86000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P06_01_2011To06_30_2011_ConsultantsMemberusgaapProductOrServiceAxis" id="Factid_670" unitRef="shares" decimals="INF">400000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses contextRef="P06_01_2011To06_30_2011_ConsultantsMemberusgaapProductOrServiceAxis" id="Factid_671" unitRef="USD" decimals="-3">192000</bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P06_01_2011To06_30_2011_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_672" unitRef="shares" decimals="INF">10870</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P06_01_2011To06_30_2011_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_673" unitRef="USD" decimals="-3">5000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P01_01_2011To12_31_2011_HadasitMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_674" unitRef="shares" decimals="INF">1500000</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2011To12_31_2011_HadasitMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_675" unitRef="USD_per_Share" decimals="3">0.001</invest:InvestmentWarrantsExercisePrice>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P12_01_2010To12_31_2010_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_676" unitRef="USD" decimals="-3">40000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:NumberOfWarrantsVestOverCourseOfTrails contextRef="P01_01_2011To12_31_2011_EnrollmentOfOneThirdOfPatientsMemberusgaapAwardTypeAxis" id="Factid_677" unitRef="shares" decimals="INF">500000</bcli:NumberOfWarrantsVestOverCourseOfTrails>

  <bcli:NumberOfWarrantsVestOverCourseOfTrails contextRef="P01_01_2011To12_31_2011_EnrollmentOfAllPatientsMemberusgaapAwardTypeAxis" id="Factid_678" unitRef="shares" decimals="INF">500000</bcli:NumberOfWarrantsVestOverCourseOfTrails>

  <bcli:NumberOfWarrantsVestOverCourseOfTrails contextRef="P01_01_2011To12_31_2011_CompletionOfStudyMemberusgaapAwardTypeAxis" id="Factid_679" unitRef="shares" decimals="INF">500000</bcli:NumberOfWarrantsVestOverCourseOfTrails>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2013To01_31_2013_ConsultantsMemberusgaapProductOrServiceAxis" id="Factid_680" unitRef="shares" decimals="INF">216000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses contextRef="P01_01_2013To01_31_2013_ConsultantsMemberusgaapProductOrServiceAxis" id="Factid_681" unitRef="USD" decimals="-3">54000</bcli:StockBasedCompensationRecordedInResearchDevelopmentExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P02_01_2013To02_28_2013_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_682" unitRef="shares" decimals="INF">126111</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P02_01_2013To02_28_2013_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_683" unitRef="USD" decimals="-3">200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P03_01_2013To03_31_2013_LegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_684" unitRef="shares" decimals="INF">193696</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P01_01_2013To09_30_2013_LegalAdvisorMemberusgaapProductOrServiceAxis" id="Factid_685" unitRef="USD" decimals="-3">22000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P03_01_2013To03_31_2013_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_686" unitRef="shares" decimals="INF">400000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P01_01_2013To09_30_2013_ServiceProviderMemberusgaapProductOrServiceAxis" id="Factid_687" unitRef="USD" decimals="-3">92000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_688"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;A summary of the Company's option activity related to options to employees and directors, and related information is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.97in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="5"&gt; &lt;div&gt;For&amp;#160;the&amp;#160;nine&amp;#160;months&amp;#160;ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="5"&gt; &lt;div&gt;September&amp;#160;30,&amp;#160;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Amount&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Outstanding at beginning of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,751,665&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.1803&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,626,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.2656&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(4,006,667)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.2898&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Outstanding at end of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,371,664&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.1721&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;96,166&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"&gt; &lt;div&gt;Vested and expected-to-vest at end of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,943,609&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.1764&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;67,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <bcli:ScheduleOfWarrantsIssuedToInvestorsServiceProvidersTableTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_689"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 163.2pt; TEXT-INDENT: -28.35pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Warrants to investors and service providers and investors:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%"&gt; &lt;div&gt;Issuance&amp;#160;date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;issued&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Price&amp;#160;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;through&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;November-December 2004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,600,845&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,396,010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;204,835&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00005 - 0.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February-December 2005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,058,471&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;173,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,548,308&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;337,163&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.15 - 2.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;337,163&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Jun - Dec 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February-December 2006&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,686,355&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;727,696&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;478,659&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;480,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.005 &amp;#150; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;480,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Feb - May 2016&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;March 2007&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,803,300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,003,300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,800,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.15 - 0.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,800,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;May 2015 &amp;#150; Oct 2017&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2008&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.15 - 0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;May 2015 &amp;#150; Sep 2018&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;Apr-Oct 2009&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,937,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;100,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,837,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.067 &amp;#150; 0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,837,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;May 2015 &amp;#150; Oct 2019&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: top; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;January 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;125,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Feb 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Apr 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;January 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,537,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,537,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,537,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;May 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;641,026&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;641,026&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.39&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,407,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;946,834&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,460,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.28&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;February 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,815,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,815,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Apr 2021&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Apr 2022&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;July 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;493,966&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;493,966&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.348&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;493,966&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Jul 2014&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;July 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;232,758&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;232,758&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;232,758&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Jan 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;July 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,864,228&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,864,228&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,864,228&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Jan 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;Feb 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;833,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;833,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;833,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Oct 2015&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;April 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;33,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,889&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;April 2023&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;August 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,647,058&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,647,058&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,647,058&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;August 2016&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;112,742,177&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,468,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;27,401,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;68,871,843&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;68,352,398&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcli:ScheduleOfWarrantsIssuedToInvestorsServiceProvidersTableTextBlock>

  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_690"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The total stock-based compensation expense, related to shares, options and warrants granted to employees, directors and service providers, was comprised, at each period, as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 141.75pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.79in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Period&amp;#160;from&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;September&amp;#160;22,&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2000&amp;#160;(inception&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;Nine&amp;#160;months&amp;#160;ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;Three&amp;#160;months&amp;#160;ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;date)&amp;#160;through&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;Unaudited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"&gt; &lt;div&gt;Unaudited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Unaudited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;101&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,867&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;521&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;441&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(71)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;145&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11,179&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;Financial expenses, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;248&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;Total stock-based&lt;br/&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160;compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;622&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;485&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(64)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;164&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29,294&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>

  <invest:InvestmentWarrantsExercisePrice contextRef="P08_01_2013To08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_691" unitRef="USD_per_Share" decimals="2">0.25</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2005To04_30_2005_USStockOptionAndIncentivePlanMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_692" unitRef="shares" decimals="INF">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P08_01_2011To08_31_2011_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_693" unitRef="USD" decimals="-3">26000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P08_01_2012To08_31_2012_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_694" unitRef="USD" decimals="-3">105000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P08_01_2012To08_31_2012_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_695" unitRef="USD" decimals="-3">16000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses contextRef="P08_01_2012To08_31_2012_ManagementMemberusgaapTitleOfIndividualAxis" id="Factid_696" unitRef="USD" decimals="-3">198000</bcli:StockBasedCompensationRecordedInGeneralAndAdministrativeExpenses>

  <invest:InvestmentWarrantsExercisePrice contextRef="P02_01_2010To02_28_2010_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_697" unitRef="USD_per_Share" decimals="2">0.50</invest:InvestmentWarrantsExercisePrice>

  <bcli:CommonStockFrequencyOfPeriodicIssuance contextRef="P01_01_2010To01_31_2010_PublicRelationsAdvisorMemberusgaapProductOrServiceAxis" id="Factid_698">monthly</bcli:CommonStockFrequencyOfPeriodicIssuance>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_01_2013To08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_699" unitRef="USD" decimals="-6">4000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2013To08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_700" unitRef="shares" decimals="INF">23529411</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_701" unitRef="USD_per_Share" decimals="5">0.00005</us-gaap:CommonStockParOrStatedValuePerShare>

  <bcli:CommonStockPurchasePrice contextRef="P08_01_2013To08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_702" unitRef="USD_per_Share" decimals="2">0.17</bcli:CommonStockPurchasePrice>

  <bcli:WarrantsIssuedToPurchaseOfCommonStock contextRef="P08_01_2013To08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_703" unitRef="shares" decimals="INF">17647058</bcli:WarrantsIssuedToPurchaseOfCommonStock>

  <bcli:WarrantsToPurchaseCommonStockSharesRatio contextRef="P08_01_2013To08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_704" unitRef="shares" decimals="INF">0.75</bcli:WarrantsToPurchaseCommonStockSharesRatio>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P08_01_2013To08_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_705" unitRef="USD" decimals="-5">3300000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2012" id="Factid_706" unitRef="shares" decimals="INF">4751665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013" id="Factid_707" unitRef="shares" decimals="INF">4626666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P01_01_2013To09_30_2013" id="Factid_708" unitRef="shares" decimals="INF">0</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013" id="Factid_709" unitRef="shares" decimals="INF">4006667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn09_30_2013" id="Factid_710" unitRef="shares" decimals="INF">5371664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="PAsOn09_30_2013" id="Factid_711" unitRef="shares" decimals="INF">4943609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2012" id="Factid_712" unitRef="USD_per_Share" decimals="4">0.1803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To09_30_2013" id="Factid_713" unitRef="USD_per_Share" decimals="4">0.2656</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To09_30_2013" id="Factid_714" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To09_30_2013" id="Factid_715" unitRef="USD_per_Share" decimals="4">0.2898</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn09_30_2013" id="Factid_716" unitRef="USD_per_Share" decimals="4">0.1721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="PAsOn09_30_2013" id="Factid_717" unitRef="USD_per_Share" decimals="4">0.1764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn09_30_2013" id="Factid_718" unitRef="USD" decimals="-3">96166000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="PAsOn09_30_2013" id="Factid_719" unitRef="USD" decimals="-3">67341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_720" unitRef="shares" decimals="INF">14600845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_721" unitRef="shares" decimals="INF">3058471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_722" unitRef="shares" decimals="INF">1686355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_723" unitRef="shares" decimals="INF">14803300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_724" unitRef="shares" decimals="INF">9175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_725" unitRef="shares" decimals="INF">4937500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateJan2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_726" unitRef="shares" decimals="INF">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_727" unitRef="shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_728" unitRef="shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_729" unitRef="shares" decimals="INF">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_730" unitRef="shares" decimals="INF">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateJan2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_731" unitRef="shares" decimals="INF">4537500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_732" unitRef="shares" decimals="INF">641026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_733" unitRef="shares" decimals="INF">6407500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_734" unitRef="shares" decimals="INF">12815000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_735" unitRef="shares" decimals="INF">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateApril2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_736" unitRef="shares" decimals="INF">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_737" unitRef="shares" decimals="INF">493966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_738" unitRef="shares" decimals="INF">232758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_739" unitRef="shares" decimals="INF">14864228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_740" unitRef="shares" decimals="INF">833334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateApril2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_741" unitRef="shares" decimals="INF">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateAugust2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_742" unitRef="shares" decimals="INF">17647058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <bcli:NumberOfWarrantsIssuedTotal contextRef="P01_01_2013To09_30_2013" id="Factid_743" unitRef="shares" decimals="INF">112742177</bcli:NumberOfWarrantsIssuedTotal>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_744" unitRef="shares" decimals="INF">14396010</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_745" unitRef="shares" decimals="INF">173000</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_746" unitRef="shares" decimals="INF">727696</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_747" unitRef="shares" decimals="INF">100000</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_748" unitRef="shares" decimals="INF">125000</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_749" unitRef="shares" decimals="INF">946834</bcli:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross>

  <bcli:WarrantExercisedTotal contextRef="P01_01_2013To09_30_2013" id="Factid_750" unitRef="shares" decimals="INF">16468540</bcli:WarrantExercisedTotal>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_751" unitRef="shares" decimals="INF">204835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_752" unitRef="shares" decimals="INF">2548308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_753" unitRef="shares" decimals="INF">478659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_754" unitRef="shares" decimals="INF">1003300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateJan2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_755" unitRef="shares" decimals="INF">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_756" unitRef="shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_757" unitRef="shares" decimals="INF">641026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_758" unitRef="shares" decimals="INF">5460666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_759" unitRef="shares" decimals="INF">12815000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <bcli:WarrantForfeitedTotal contextRef="P01_01_2013To09_30_2013" id="Factid_760" unitRef="shares" decimals="INF">27401794</bcli:WarrantForfeitedTotal>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_761" unitRef="shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_762" unitRef="shares" decimals="INF">337163</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_763" unitRef="shares" decimals="INF">480000</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_764" unitRef="shares" decimals="INF">13800000</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_765" unitRef="shares" decimals="INF">9175000</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_766" unitRef="shares" decimals="INF">4837500</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateJan2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_767" unitRef="shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFeb2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_768" unitRef="shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFeb2010OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_769" unitRef="shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFeb2010TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_770" unitRef="shares" decimals="INF">1500000</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateApr2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_771" unitRef="shares" decimals="INF">33334</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateJan2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_772" unitRef="shares" decimals="INF">4537500</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFeb2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_773" unitRef="shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_774" unitRef="shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFeb2011TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_775" unitRef="shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateApr2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_776" unitRef="shares" decimals="INF">33334</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateApril2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_777" unitRef="shares" decimals="INF">33334</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateJuly2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_778" unitRef="shares" decimals="INF">493966</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateJuly2012OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_779" unitRef="shares" decimals="INF">232758</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateJuly2012TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_780" unitRef="shares" decimals="INF">14864228</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateFeb2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_781" unitRef="shares" decimals="INF">833334</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateApril2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_782" unitRef="shares" decimals="INF">33334</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn09_30_2013_IssuanceDateAugust2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_783" unitRef="shares" decimals="INF">17647058</us-gaap:ClassOfWarrantOrRightOutstanding>

  <bcli:WarrantsOutstandingTotal contextRef="PAsOn09_30_2013" id="Factid_784" unitRef="shares" decimals="INF">68871843</bcli:WarrantsOutstandingTotal>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_785" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_786" unitRef="shares" decimals="INF">337163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_787" unitRef="shares" decimals="INF">480000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_788" unitRef="shares" decimals="INF">13800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_789" unitRef="shares" decimals="INF">9175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_790" unitRef="shares" decimals="INF">4837500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateJan2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_791" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFeb2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_792" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFeb2010OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_793" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFeb2010TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_794" unitRef="shares" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateApr2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_795" unitRef="shares" decimals="INF">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateJan2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_796" unitRef="shares" decimals="INF">4537500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFeb2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_797" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_798" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFeb2011TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_799" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateApr2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_800" unitRef="shares" decimals="INF">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateApril2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_801" unitRef="shares" decimals="INF">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateJuly2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_802" unitRef="shares" decimals="INF">493966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateJuly2012OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_803" unitRef="shares" decimals="INF">232758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateJuly2012TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_804" unitRef="shares" decimals="INF">14864228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateFeb2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_805" unitRef="shares" decimals="INF">833334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateApril2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_806" unitRef="shares" decimals="INF">13889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013_IssuanceDateAugust2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_807" unitRef="shares" decimals="INF">17647058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <bcli:WarrantsExercisableTotal contextRef="PAsOn09_30_2013" id="Factid_808" unitRef="shares" decimals="INF">68352398</bcli:WarrantsExercisableTotal>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2005MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_809">Jun - Dec 2015</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFebDec2006MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_810">Feb - May 2016</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateMar2007MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_811">May 2015 &amp;#150; Oct 2017</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2008MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_812">May 2015 &amp;#150; Sep 2018</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateAprOct2009MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_813">May 2015 &amp;#150; Oct 2019</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateJan2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_814">-</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_815">-</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_816">-</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_817">Feb 2020</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_818">Apr 2020</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateJan2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_819">May 2015</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_820">-</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_821">-</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_822">-</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_823">Apr 2021</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateApril2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_824">Apr 2022</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_825">Jul 2014</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_826">Jan 2015</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_827">Jan 2015</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_828">Oct 2015</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateApril2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_829">April 2023</bcli:WarrantExercisableTerm>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateAugust2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_830">August 2016</bcli:WarrantExercisableTerm>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateJan2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_831" unitRef="USD_per_Share" decimals="1">0.5</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_832" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_833" unitRef="USD_per_Share" decimals="1">0.5</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2010TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_834" unitRef="USD_per_Share" decimals="3">0.001</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2010MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_835" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateJan2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_836" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_837" unitRef="USD_per_Share" decimals="2">0.39</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_838" unitRef="USD_per_Share" decimals="2">0.28</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2011TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_839" unitRef="USD_per_Share" decimals="1">0.5</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateApr2011MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_840" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateApril2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_841" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_842" unitRef="USD_per_Share" decimals="3">0.348</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012OneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_843" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateJuly2012TwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_844" unitRef="USD_per_Share" decimals="2">0.29</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateFeb2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_845" unitRef="USD_per_Share" decimals="1">0.5</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateApril2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_846" unitRef="USD_per_Share" decimals="5">0.00005</invest:InvestmentWarrantsExercisePrice>

  <invest:InvestmentWarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_IssuanceDateAugust2013MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_847" unitRef="USD_per_Share" decimals="2">0.25</invest:InvestmentWarrantsExercisePrice>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To09_30_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_848" unitRef="USD" decimals="-3">101000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To09_30_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_849" unitRef="USD" decimals="-3">521000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To09_30_2013_InterestExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_850" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2013To09_30_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_851" unitRef="USD" decimals="-3">7000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2013To09_30_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_852" unitRef="USD" decimals="-3">-71000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2013To09_30_2013_InterestExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_853" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To09_30_2012_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_854" unitRef="USD" decimals="-3">44000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To09_30_2012_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_855" unitRef="USD" decimals="-3">441000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To09_30_2012_InterestExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_856" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2012To09_30_2012_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_857" unitRef="USD" decimals="-3">19000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2012To09_30_2012_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_858" unitRef="USD" decimals="-3">145000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2012To09_30_2012_InterestExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_859" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P09_23_2000To09_30_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_860" unitRef="USD" decimals="-3">17867000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P09_23_2000To09_30_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_861" unitRef="USD" decimals="-3">11179000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P09_23_2000To09_30_2013_InterestExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_862" unitRef="USD" decimals="-3">248000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To09_30_2013" id="Factid_863" unitRef="USD" decimals="-3">622000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To09_30_2012" id="Factid_864" unitRef="USD" decimals="-3">485000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2013To09_30_2013" id="Factid_865" unitRef="USD" decimals="-3">-64000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2012To09_30_2012" id="Factid_866" unitRef="USD" decimals="-3">164000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P09_23_2000To09_30_2013" id="Factid_867" unitRef="USD" decimals="-3">29294000</us-gaap:ShareBasedCompensation>

  <bcli:WarrantExercisableTerm contextRef="P01_01_2013To09_30_2013_IssuanceDateNovDec2004MemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_868">-</bcli:WarrantExercisableTerm>

  <bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInJune contextRef="P04_01_2004To03_31_2005" id="Factid_869" unitRef="USD_per_Share" decimals="2">0.01</bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInJune>

  <bcli:StockIssuedExpenses contextRef="P04_01_2004To03_31_2005" id="Factid_870" unitRef="USD" decimals="0">25000</bcli:StockIssuedExpenses>

  <bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne contextRef="P04_01_2004To03_31_2005" id="Factid_871" unitRef="USD_per_Share" decimals="2">0.75</bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne>

  <bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInMay contextRef="P04_01_2005To03_31_2006" id="Factid_872" unitRef="USD_per_Share" decimals="1">0.8</bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInMay>

  <bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInJuly contextRef="P04_01_2005To03_31_2006" id="Factid_873" unitRef="USD_per_Share" decimals="1">0.6</bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInJuly>

  <bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInSeptember contextRef="P04_01_2005To03_31_2006" id="Factid_874" unitRef="USD_per_Share" decimals="1">0.8</bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInSeptember>

  <bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInDecember contextRef="P04_01_2005To03_31_2006" id="Factid_875" unitRef="USD_per_Share" decimals="1">0.8</bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInDecember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJune contextRef="P04_01_2004To03_31_2005" id="Factid_876" unitRef="USD" decimals="-3">60000</bcli:StockIssuedDuringPeriodForPrivatePlacementInJune>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJune contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_877" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInJune>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJune contextRef="P04_01_2004To03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_878" unitRef="USD" decimals="-3">60000</bcli:StockIssuedDuringPeriodForPrivatePlacementInJune>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJune contextRef="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_879" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInJune>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJune contextRef="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_880" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInJune>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInJune contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_881" unitRef="shares" decimals="INF">8510000</bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInJune>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2004To03_31_2005" id="Factid_882" unitRef="USD" decimals="-3">7000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_883" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2004To03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_884" unitRef="USD" decimals="-3">7000</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_885" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital contextRef="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_886" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalContributionOfCapital>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P04_01_2004To03_31_2005" id="Factid_887" unitRef="USD" decimals="-3">1418000</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_888" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P04_01_2004To03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_889" unitRef="USD" decimals="-3">1418000</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_890" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_891" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementSharesIssuesOne contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_892" unitRef="shares" decimals="INF">1894808</bcli:StockIssuedDuringPeriodForPrivatePlacementSharesIssuesOne>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2004To03_31_2005" id="Factid_893" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_894" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_895" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodValue contextRef="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_896" unitRef="USD" decimals="-3">0</bcli:StockCancelledDuringPeriodValue>

  <bcli:StockCancelledDuringPeriodShares contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_897" unitRef="shares" decimals="INF">1800000</bcli:StockCancelledDuringPeriodShares>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2004To03_31_2005" id="Factid_898" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_899" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2004To03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_900" unitRef="USD" decimals="-3">5979000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_901" unitRef="USD" decimals="-3">-5979000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_902" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_903" unitRef="shares" decimals="INF">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2004To03_31_2005" id="Factid_904" unitRef="USD" decimals="-3">584000</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_905" unitRef="USD" decimals="-3">0</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2004To03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_906" unitRef="USD" decimals="-3">0</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_907" unitRef="USD" decimals="-3">584000</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_908" unitRef="USD" decimals="-3">0</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2004To03_31_2005" id="Factid_909" unitRef="USD" decimals="-3">17506000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_910" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2004To03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_911" unitRef="USD" decimals="-3">17506000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_912" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_913" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_914" unitRef="shares" decimals="INF">2025000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2004To03_31_2005" id="Factid_915" unitRef="USD" decimals="-3">-18840000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2004To03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_916" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2004To03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_917" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2004To03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_918" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2004To03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_919" unitRef="USD" decimals="-3">-18840000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2005" id="Factid_920" unitRef="USD" decimals="-3">704000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_921" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2005_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_922" unitRef="USD" decimals="-3">25101000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2005_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_923" unitRef="USD" decimals="-3">-5395000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2005_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_924" unitRef="USD" decimals="-3">-19003000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2005_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_925" unitRef="shares" decimals="INF">20867808</us-gaap:SharesOutstanding>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInMay contextRef="P04_01_2005To03_31_2006" id="Factid_926" unitRef="USD" decimals="-3">149000</bcli:StockIssuedDuringPeriodForPrivatePlacementInMay>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInMay contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_927" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInMay>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInMay contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_928" unitRef="USD" decimals="-3">149000</bcli:StockIssuedDuringPeriodForPrivatePlacementInMay>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInMay contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_929" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInMay>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInMay contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_930" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInMay>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInMay contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_931" unitRef="shares" decimals="INF">186875</bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInMay>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly contextRef="P04_01_2005To03_31_2006" id="Factid_932" unitRef="USD" decimals="-3">99000</bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_933" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_934" unitRef="USD" decimals="-3">99000</bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_935" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_936" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInJuly>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInJuly contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_937" unitRef="shares" decimals="INF">165000</bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInJuly>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember contextRef="P04_01_2005To03_31_2006" id="Factid_938" unitRef="USD" decimals="-3">225000</bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_939" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_940" unitRef="USD" decimals="-3">225000</bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_941" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_942" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInSeptember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInSeptember contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_943" unitRef="shares" decimals="INF">312500</bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInSeptember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember contextRef="P04_01_2005To03_31_2006" id="Factid_944" unitRef="USD" decimals="-3">135000</bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_945" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_946" unitRef="USD" decimals="-3">135000</bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_947" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_948" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementInDecember>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInDecember contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_949" unitRef="shares" decimals="INF">187500</bcli:StockIssuedDuringPeriodForPrivatePlacementSharesInDecember>

  <bcli:ForfeitureOfOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006" id="Factid_950" unitRef="USD" decimals="-3">0</bcli:ForfeitureOfOptionsGrantedToEmployees>

  <bcli:ForfeitureOfOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_951" unitRef="USD" decimals="-3">0</bcli:ForfeitureOfOptionsGrantedToEmployees>

  <bcli:ForfeitureOfOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_952" unitRef="USD" decimals="-3">-3363000</bcli:ForfeitureOfOptionsGrantedToEmployees>

  <bcli:ForfeitureOfOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_953" unitRef="USD" decimals="-3">3363000</bcli:ForfeitureOfOptionsGrantedToEmployees>

  <bcli:ForfeitureOfOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_954" unitRef="USD" decimals="-3">0</bcli:ForfeitureOfOptionsGrantedToEmployees>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2005To03_31_2006" id="Factid_955" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_956" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_957" unitRef="USD" decimals="-3">486000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_958" unitRef="USD" decimals="-3">-486000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_959" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_960" unitRef="shares" decimals="INF">200000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006" id="Factid_961" unitRef="USD" decimals="-3">1174000</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_962" unitRef="USD" decimals="-3">0</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_963" unitRef="USD" decimals="-3">51000</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_964" unitRef="USD" decimals="-3">1123000</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_965" unitRef="USD" decimals="-3">0</bcli:AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2005To03_31_2006" id="Factid_966" unitRef="USD" decimals="-3">662000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_967" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_968" unitRef="USD" decimals="-3">662000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_969" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_970" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_971" unitRef="shares" decimals="INF">934904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication contextRef="P04_01_2005To03_31_2006" id="Factid_972" unitRef="USD" decimals="-3">-7906000</bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication>

  <bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_973" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication>

  <bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_974" unitRef="USD" decimals="-3">-7906000</bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2005To03_31_2006" id="Factid_975" unitRef="USD" decimals="-3">164000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_976" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_977" unitRef="USD" decimals="-3">164000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_978" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_979" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2005To03_31_2006" id="Factid_980" unitRef="USD" decimals="-3">-3317000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2005To03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_981" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2005To03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_982" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2005To03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_983" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2005To03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_984" unitRef="USD" decimals="-3">-3317000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2006" id="Factid_985" unitRef="USD" decimals="-3">-7911000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_986" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_987" unitRef="USD" decimals="-3">15803000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_988" unitRef="USD" decimals="-3">-1395000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_989" unitRef="USD" decimals="-3">-22320000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_990" unitRef="shares" decimals="INF">22854587</us-gaap:SharesOutstanding>

  <bcli:EliminationOfDeferredStockCompensationDueToImplementation contextRef="P04_01_2006To12_31_2006" id="Factid_991" unitRef="USD" decimals="-3">0</bcli:EliminationOfDeferredStockCompensationDueToImplementation>

  <bcli:EliminationOfDeferredStockCompensationDueToImplementation contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_992" unitRef="USD" decimals="-3">0</bcli:EliminationOfDeferredStockCompensationDueToImplementation>

  <bcli:EliminationOfDeferredStockCompensationDueToImplementation contextRef="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_993" unitRef="USD" decimals="-3">-1395000</bcli:EliminationOfDeferredStockCompensationDueToImplementation>

  <bcli:EliminationOfDeferredStockCompensationDueToImplementation contextRef="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_994" unitRef="USD" decimals="-3">1395000</bcli:EliminationOfDeferredStockCompensationDueToImplementation>

  <bcli:EliminationOfDeferredStockCompensationDueToImplementation contextRef="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_995" unitRef="USD" decimals="-3">0</bcli:EliminationOfDeferredStockCompensationDueToImplementation>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2006To12_31_2006" id="Factid_996" unitRef="USD" decimals="-3">1168000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_997" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_998" unitRef="USD" decimals="-3">1168000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_999" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1000" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1001" unitRef="shares" decimals="INF">200000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication contextRef="P04_01_2006To12_31_2006" id="Factid_1002" unitRef="USD" decimals="-3">7191000</bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication>

  <bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1003" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication>

  <bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication contextRef="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1004" unitRef="USD" decimals="-3">7191000</bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication>

  <bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication contextRef="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1005" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication>

  <bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication contextRef="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1006" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2006To12_31_2006" id="Factid_1007" unitRef="USD" decimals="-3">453000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1008" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1009" unitRef="USD" decimals="-3">453000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1010" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1011" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1012" unitRef="shares" decimals="INF">1147225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P04_01_2006To12_31_2006" id="Factid_1013" unitRef="USD" decimals="-3">11000</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1014" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1015" unitRef="USD" decimals="-3">11000</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1016" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1017" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder contextRef="P04_01_2006To12_31_2006" id="Factid_1018" unitRef="USD" decimals="-3">110000</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1019" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder contextRef="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1020" unitRef="USD" decimals="-3">110000</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder contextRef="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1021" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder contextRef="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1022" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2006To12_31_2006" id="Factid_1023" unitRef="USD" decimals="-3">1086000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1024" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1025" unitRef="USD" decimals="-3">1086000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1026" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1027" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2006To12_31_2006" id="Factid_1028" unitRef="USD" decimals="-3">-3924000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2006To12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1029" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2006To12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1030" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2006To12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1031" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2006To12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1032" unitRef="USD" decimals="-3">-3924000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2006" id="Factid_1033" unitRef="USD" decimals="-3">-1816000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1034" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2006_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1035" unitRef="USD" decimals="-3">24427000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2006_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1036" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2006_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1037" unitRef="USD" decimals="-3">-26244000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2006_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1038" unitRef="shares" decimals="INF">24201812</us-gaap:SharesOutstanding>

  <bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne contextRef="P01_01_2007To12_31_2007" id="Factid_1039" unitRef="USD_per_Share" decimals="4">0.1818</bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne>

  <bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne contextRef="P01_01_2008To12_31_2008" id="Factid_1040" unitRef="USD_per_Share" decimals="4">0.1818</bcli:PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne>

  <bcli:PricePerShareOfSubscriptionOfSharesDuringPeriodForPrivatePlacement contextRef="P01_01_2008To12_31_2008" id="Factid_1041" unitRef="USD_per_Share" decimals="4">0.1818</bcli:PricePerShareOfSubscriptionOfSharesDuringPeriodForPrivatePlacement>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2007To12_31_2007" id="Factid_1042" unitRef="USD" decimals="-3">1446000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1043" unitRef="USD" decimals="-3">1446000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1044" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1045" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1046" unitRef="shares" decimals="INF">544095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P01_01_2007To12_31_2007" id="Factid_1047" unitRef="USD" decimals="-3">109000</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1048" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1049" unitRef="USD" decimals="-3">109000</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1050" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder contextRef="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1051" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2007To12_31_2007" id="Factid_1052" unitRef="USD" decimals="-3">1232000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1053" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1054" unitRef="USD" decimals="-3">1232000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1055" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1056" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1057" unitRef="shares" decimals="INF">200000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P01_01_2007To12_31_2007" id="Factid_1058" unitRef="USD" decimals="-3">407000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1059" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1060" unitRef="USD" decimals="-3">407000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1061" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1062" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2007To12_31_2007" id="Factid_1063" unitRef="USD" decimals="-3">214000</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1064" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1065" unitRef="USD" decimals="-3">214000</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1066" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1067" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1068" unitRef="shares" decimals="INF">3832621</bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2007To12_31_2007" id="Factid_1069" unitRef="USD" decimals="-3">2000000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1070" unitRef="USD" decimals="-3">1000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1071" unitRef="USD" decimals="-3">1999000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1072" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1073" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodSharesPrivatePlacement contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1074" unitRef="shares" decimals="INF">11500000</bcli:StockIssuedDuringPeriodSharesPrivatePlacement>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2007To12_31_2007" id="Factid_1075" unitRef="USD" decimals="-3">-6244000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1076" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1077" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1078" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1079" unitRef="USD" decimals="-3">-6244000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2007" id="Factid_1080" unitRef="USD" decimals="-3">-2428000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1081" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1082" unitRef="USD" decimals="-3">30058000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1083" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1084" unitRef="USD" decimals="-3">-32488000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1085" unitRef="shares" decimals="INF">41004409</us-gaap:SharesOutstanding>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2008To12_31_2008" id="Factid_1086" unitRef="USD" decimals="-3">33000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1087" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1088" unitRef="USD" decimals="-3">33000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1089" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1090" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1091" unitRef="shares" decimals="INF">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2008To12_31_2008" id="Factid_1092" unitRef="USD" decimals="-3">731000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1093" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1094" unitRef="USD" decimals="-3">731000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1095" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1096" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1097" unitRef="shares" decimals="INF">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2008To12_31_2008" id="Factid_1098" unitRef="USD" decimals="-3">1276000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1099" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1100" unitRef="USD" decimals="-3">1276000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1101" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1102" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1103" unitRef="shares" decimals="INF">3644610</bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2007To12_31_2007" id="Factid_1104" unitRef="USD" decimals="-3">224000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1105" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2007To12_31_2007_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1106" unitRef="USD" decimals="-3">224000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2007To12_31_2007_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1107" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2007To12_31_2007_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1108" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans contextRef="P01_01_2007To12_31_2007_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1109" unitRef="shares" decimals="INF">725881</bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2008To12_31_2008" id="Factid_1110" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1111" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1112" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1113" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1114" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1115" unitRef="shares" decimals="INF">1860000</bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2008To12_31_2008" id="Factid_1116" unitRef="USD" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1117" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1118" unitRef="USD" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1119" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1120" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1121" unitRef="shares" decimals="INF">17399</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2008To12_31_2008" id="Factid_1122" unitRef="USD" decimals="-3">1500000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1123" unitRef="USD" decimals="-3">1000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1124" unitRef="USD" decimals="-3">1499000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1125" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1126" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodSharesPrivatePlacement contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1127" unitRef="shares" decimals="INF">8625000</bcli:StockIssuedDuringPeriodSharesPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2008To12_31_2008" id="Factid_1128" unitRef="USD" decimals="-3">281000</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1129" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1130" unitRef="USD" decimals="-3">281000</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1131" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1132" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2008To12_31_2008" id="Factid_1133" unitRef="USD" decimals="-3">-3472000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2008To12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1134" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2008To12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1135" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2008To12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1136" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2008To12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1137" unitRef="USD" decimals="-3">-3472000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2008" id="Factid_1138" unitRef="USD" decimals="-3">-2076000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1139" unitRef="USD" decimals="-3">3000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2008_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1140" unitRef="USD" decimals="-3">33881000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2008_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1141" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2008_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1142" unitRef="USD" decimals="-3">-35960000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2008_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1143" unitRef="shares" decimals="INF">55241418</us-gaap:SharesOutstanding>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2009To12_31_2009" id="Factid_1144" unitRef="USD" decimals="-3">775000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1145" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2009To12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1146" unitRef="USD" decimals="-3">775000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2009To12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1147" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2009To12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1148" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1149" unitRef="shares" decimals="INF">5284284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2009To12_31_2009" id="Factid_1150" unitRef="USD" decimals="-3">409000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1151" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2009To12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1152" unitRef="USD" decimals="-3">409000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2009To12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1153" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2009To12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1154" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1155" unitRef="shares" decimals="INF">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2009To12_31_2009" id="Factid_1156" unitRef="USD" decimals="-3">200000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1157" unitRef="USD" xsi:nil="true" />

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2009To12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1158" unitRef="USD" decimals="-3">200000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2009To12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1159" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2009To12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1160" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1161" unitRef="shares" decimals="INF">2500000</bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2009To12_31_2009" id="Factid_1162" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1163" unitRef="USD" xsi:nil="true" />

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2009To12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1164" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2009To12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1165" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2009To12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1166" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1167" unitRef="shares" decimals="INF">3366783</bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2009To12_31_2009" id="Factid_1168" unitRef="USD" decimals="-3">1000</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1169" unitRef="USD" decimals="-3">1000</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2009To12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1170" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2009To12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1171" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2009To12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1172" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementSharesIssuesOne contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1173" unitRef="shares" decimals="INF">9916667</bcli:StockIssuedDuringPeriodForPrivatePlacementSharesIssuesOne>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2009To12_31_2009" id="Factid_1174" unitRef="USD" decimals="-3">729000</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1175" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2009To12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1176" unitRef="USD" decimals="-3">729000</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2009To12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1177" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2009To12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1178" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2009To12_31_2009" id="Factid_1179" unitRef="USD" decimals="-3">-1781000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2009To12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1180" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2009To12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1181" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2009To12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1182" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2009To12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1183" unitRef="USD" decimals="-3">-1781000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2009" id="Factid_1184" unitRef="USD" decimals="-3">-1743000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1185" unitRef="USD" decimals="-3">4000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2009_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1186" unitRef="USD" decimals="-3">35994000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2009_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1187" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2009_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1188" unitRef="USD" decimals="-3">-37741000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2009_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1189" unitRef="shares" decimals="INF">76309152</us-gaap:SharesOutstanding>

  <bcli:PricePerShareOfSubscriptionOfSharesDuringPeriodForPrivatePlacement contextRef="P01_01_2010To12_31_2010" id="Factid_1190" unitRef="USD_per_Share" decimals="2">0.12</bcli:PricePerShareOfSubscriptionOfSharesDuringPeriodForPrivatePlacement>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1191" unitRef="shares" decimals="INF">443333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2010To12_31_2010" id="Factid_1192" unitRef="USD" decimals="-3">96000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1193" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1194" unitRef="USD" decimals="-3">96000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1195" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1196" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1197" unitRef="shares" decimals="INF">466667</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2010To12_31_2010" id="Factid_1198" unitRef="USD" decimals="-3">388000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1199" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1200" unitRef="USD" decimals="-3">388000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1201" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1202" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementSharesIssuesOne contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1203" unitRef="shares" decimals="INF">7250000</bcli:StockIssuedDuringPeriodForPrivatePlacementSharesIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2010To12_31_2010" id="Factid_1204" unitRef="USD" decimals="-3">1751000</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1205" unitRef="USD" decimals="-3">1000</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1206" unitRef="USD" decimals="-3">1750000</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1207" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1208" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne>

  <bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleNote contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1209" unitRef="shares" decimals="INF">402385</bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2010To12_31_2010" id="Factid_1210" unitRef="USD" decimals="-3">135000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1211" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1212" unitRef="USD" decimals="-3">135000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1213" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1214" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1215" unitRef="shares" decimals="INF">1016109</bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2010To12_31_2010" id="Factid_1216" unitRef="USD" decimals="-3">189000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1217" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1218" unitRef="USD" decimals="-3">189000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1219" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1220" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1221" unitRef="shares" decimals="INF">2475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2010To12_31_2010" id="Factid_1222" unitRef="USD" decimals="-3">400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1223" unitRef="USD" decimals="-3">400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1224" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1225" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1226" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1227" unitRef="shares" decimals="INF">1540885</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2010To12_31_2010" id="Factid_1228" unitRef="USD" decimals="-3">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1229" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1230" unitRef="USD" decimals="-3">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1231" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1232" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1233" unitRef="shares" decimals="INF">3929446</bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2010To12_31_2010" id="Factid_1234" unitRef="USD" decimals="-3">11000</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1235" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1236" unitRef="USD" decimals="-3">11000</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1237" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1238" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2010To12_31_2010" id="Factid_1239" unitRef="USD" decimals="-3">455000</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1240" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1241" unitRef="USD" decimals="-3">455000</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1242" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1243" unitRef="USD" decimals="-3">0</bcli:AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2010To12_31_2010" id="Factid_1244" unitRef="USD" decimals="-3">201000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1245" unitRef="USD" decimals="-3">0</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1246" unitRef="USD" decimals="-3">201000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1247" unitRef="USD" decimals="-3">0</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1248" unitRef="USD" decimals="-3">0</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <bcli:StockIssuedDuringPeriodSharesPreviouslySubscribedShares contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1249" unitRef="shares" decimals="INF">2000001</bcli:StockIssuedDuringPeriodSharesPreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2010To12_31_2010" id="Factid_1250" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2010To12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1251" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2010To12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1252" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2010To12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1253" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1254" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2010To12_31_2010" id="Factid_1255" unitRef="USD" decimals="-3">-2419000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2010To12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1256" unitRef="USD" decimals="-3">-2419000</us-gaap:NetIncomeLoss>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1257" unitRef="shares" decimals="INF">95832978</us-gaap:SharesOutstanding>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2010" id="Factid_1258" unitRef="USD" decimals="-3">-459000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2010_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1259" unitRef="USD" decimals="-3">5000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2010_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1260" unitRef="USD" decimals="-3">39696000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2010_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1261" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2010_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1262" unitRef="USD" decimals="-3">-40160000</us-gaap:StockholdersEquity>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1263" unitRef="shares" decimals="INF">474203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2011To12_31_2011" id="Factid_1264" unitRef="USD" decimals="-3">449000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1265" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1266" unitRef="USD" decimals="-3">449000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1267" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1268" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1269" unitRef="shares" decimals="INF">2025040</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2011To12_31_2011" id="Factid_1270" unitRef="USD" decimals="-3">1135000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1271" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1272" unitRef="USD" decimals="-3">1135000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1273" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1274" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleNote contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1275" unitRef="shares" decimals="INF">755594</bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2011To12_31_2011" id="Factid_1276" unitRef="USD" decimals="-3">140000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1277" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1278" unitRef="USD" decimals="-3">140000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1279" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1280" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleNote>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1281" unitRef="shares" decimals="INF">1648728</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2011To12_31_2011" id="Factid_1282" unitRef="USD" decimals="-3">243000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1283" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1284" unitRef="USD" decimals="-3">243000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1285" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1286" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1287" unitRef="shares" decimals="INF">1046834</bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2011To12_31_2011" id="Factid_1288" unitRef="USD" decimals="-3">272000</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1289" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1290" unitRef="USD" decimals="-3">272000</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1291" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1292" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodSharesPrivatePlacement contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1293" unitRef="shares" decimals="INF">14160933</bcli:StockIssuedDuringPeriodSharesPrivatePlacement>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2011To12_31_2011" id="Factid_1294" unitRef="USD" decimals="-3">3602000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1295" unitRef="USD" decimals="-3">1000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1296" unitRef="USD" decimals="-3">3601000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1297" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1298" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodSharesPreviouslySubscribedShares contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1299" unitRef="shares" decimals="INF">10499999</bcli:StockIssuedDuringPeriodSharesPreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2011To12_31_2011" id="Factid_1300" unitRef="USD" decimals="-3">24000</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1301" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1302" unitRef="USD" decimals="-3">24000</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1303" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1304" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValuePreviouslySubscribedShares>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2011To12_31_2011" id="Factid_1305" unitRef="USD" decimals="-3">-3918000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1306" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1307" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2011To12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1308" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1309" unitRef="USD" decimals="-3">-3918000</us-gaap:NetIncomeLoss>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1310" unitRef="shares" decimals="INF">126444309</us-gaap:SharesOutstanding>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2011" id="Factid_1311" unitRef="USD" decimals="-3">1488000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1312" unitRef="USD" decimals="-3">6000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1313" unitRef="USD" decimals="-3">45560000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2011_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1314" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1315" unitRef="USD" decimals="-3">-44078000</us-gaap:StockholdersEquity>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2012To12_31_2012" id="Factid_1316" unitRef="USD" decimals="-3">195000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1317" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1318" unitRef="USD" decimals="-3">195000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2012To12_31_2012_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1319" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1320" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1321" unitRef="shares" decimals="INF">794423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1322" unitRef="shares" decimals="INF">885000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2012To12_31_2012" id="Factid_1323" unitRef="USD" decimals="-3">560000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1324" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1325" unitRef="USD" decimals="-3">560000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2012To12_31_2012_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1326" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1327" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1328" unitRef="shares" decimals="INF">1182606</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1329" unitRef="shares" decimals="INF">959729</bcli:StockIssuedDuringPeriodSharesExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodSharesPrivatePlacement contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1330" unitRef="shares" decimals="INF">19818968</bcli:StockIssuedDuringPeriodSharesPrivatePlacement>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2012To12_31_2012" id="Factid_1331" unitRef="USD" decimals="-3">137000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1332" unitRef="USD" decimals="-3">137000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2012To12_31_2012_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1333" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1334" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1335" unitRef="USD" xsi:nil="true" />

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2012To12_31_2012" id="Factid_1336" unitRef="USD" decimals="-3">9000</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1337" unitRef="USD" xsi:nil="true" />

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1338" unitRef="USD" decimals="-3">9000</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2012To12_31_2012_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1339" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1340" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2012To12_31_2012" id="Factid_1341" unitRef="USD" decimals="-3">5023000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1342" unitRef="USD" decimals="-3">1000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1343" unitRef="USD" decimals="-3">5022000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1344" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To12_31_2012" id="Factid_1345" unitRef="USD" decimals="-3">-3430000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1346" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1347" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To12_31_2012_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1348" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1349" unitRef="USD" decimals="-3">-3430000</us-gaap:NetIncomeLoss>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1350" unitRef="shares" decimals="INF">150085035</us-gaap:SharesOutstanding>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1351" unitRef="USD" decimals="-3">7000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1352" unitRef="USD" decimals="-3">51483000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1353" unitRef="USD" decimals="-3">-47508000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1354" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1355" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1356" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1357" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1358" unitRef="USD" decimals="-3">-3682000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1359" unitRef="USD" decimals="-3">8000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1360" unitRef="USD" decimals="-3">55717000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1361" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1362" unitRef="USD" decimals="-3">-51190000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1363" unitRef="shares" decimals="INF">176243587</us-gaap:SharesOutstanding>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1364" unitRef="shares" decimals="INF">809696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2013To09_30_2013" id="Factid_1365" unitRef="USD" decimals="-3">183000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2013To09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1366" unitRef="USD" decimals="-3">183000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2013To09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1367" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="P01_01_2013To09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1368" unitRef="USD" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1369" unitRef="shares" decimals="INF">760000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsShares>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2013To09_30_2013" id="Factid_1370" unitRef="USD" decimals="-3">439000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2013To09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1371" unitRef="USD" decimals="-3">439000</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2013To09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1372" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue contextRef="P01_01_2013To09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1373" unitRef="USD" decimals="-3">0</bcli:StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue>

  <bcli:StockIssuedDuringPeriodSharesPrivatePlacement contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1374" unitRef="shares" decimals="INF">833334</bcli:StockIssuedDuringPeriodSharesPrivatePlacement>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2013To09_30_2013" id="Factid_1375" unitRef="USD" decimals="-3">250000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1376" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2013To09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1377" unitRef="USD" decimals="-3">250000</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2013To09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1378" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <bcli:StockIssuedDuringPeriodForPrivatePlacementValue contextRef="P01_01_2013To09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1379" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodForPrivatePlacementValue>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1380" unitRef="shares" decimals="INF">23529411</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To09_30_2013" id="Factid_1381" unitRef="USD" decimals="-3">3326000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1382" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1383" unitRef="USD" decimals="-3">3325000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1384" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1385" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1386" unitRef="shares" decimals="INF">126111</bcli:StockIssuedDuringPeriodSharesConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2013To09_30_2013" id="Factid_1387" unitRef="USD" decimals="-3">30000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1388" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2013To09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1389" unitRef="USD" decimals="-3">30000</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2013To09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1390" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans contextRef="P01_01_2013To09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1391" unitRef="USD" decimals="-3">0</bcli:StockIssuedDuringPeriodValueConversionOfConvertibleLoans>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2013To09_30_2013" id="Factid_1392" unitRef="USD" decimals="-3">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1393" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2013To09_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_1394" unitRef="USD" decimals="-3">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2013To09_30_2013_DeferredCompensationShareBasedPaymentsMemberusgaapStatementEquityComponentsAxis" id="Factid_1395" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2013To09_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_1396" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2013To09_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_1397" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#Factid_189" xlink:type="locator" xlink:label="loc_1" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_1">Represents an amount less than $1.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_195" xlink:type="locator" xlink:label="loc_3" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_201" xlink:type="locator" xlink:label="loc_4" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_202" xlink:type="locator" xlink:label="loc_5" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_207" xlink:type="locator" xlink:label="loc_6" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_222" xlink:type="locator" xlink:label="loc_7" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_877" xlink:type="locator" xlink:label="loc_8" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_888" xlink:type="locator" xlink:label="loc_9" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_894" xlink:type="locator" xlink:label="loc_10" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_910" xlink:type="locator" xlink:label="loc_11" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_927" xlink:type="locator" xlink:label="loc_12" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_933" xlink:type="locator" xlink:label="loc_13" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_939" xlink:type="locator" xlink:label="loc_14" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_945" xlink:type="locator" xlink:label="loc_15" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_956" xlink:type="locator" xlink:label="loc_16" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_967" xlink:type="locator" xlink:label="loc_17" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_997" xlink:type="locator" xlink:label="loc_18" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1053" xlink:type="locator" xlink:label="loc_19" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1064" xlink:type="locator" xlink:label="loc_20" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1099" xlink:type="locator" xlink:label="loc_21" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1105" xlink:type="locator" xlink:label="loc_22" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1111" xlink:type="locator" xlink:label="loc_23" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1117" xlink:type="locator" xlink:label="loc_24" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1145" xlink:type="locator" xlink:label="loc_25" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1157" xlink:type="locator" xlink:label="loc_26" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1163" xlink:type="locator" xlink:label="loc_27" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1193" xlink:type="locator" xlink:label="loc_28" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1199" xlink:type="locator" xlink:label="loc_29" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1211" xlink:type="locator" xlink:label="loc_30" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1217" xlink:type="locator" xlink:label="loc_31" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1229" xlink:type="locator" xlink:label="loc_32" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1235" xlink:type="locator" xlink:label="loc_33" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1251" xlink:type="locator" xlink:label="loc_34" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1335" xlink:type="locator" xlink:label="loc_35" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_1337" xlink:type="locator" xlink:label="loc_36" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
  </link:footnoteLink>
</xbrli:xbrl>

